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1 Introduction	
1.1 Overview	
	
The	main	topic	of	this	paper	is	the	requirement	of	industrial	application	for	pharmaceutical	
and	biotechnological	inventions,	with	a	particular	focus	on	how	the	requirement	is	being	
interpreted	by	the	technical	Board	of	Appeal	of	the	European	Patent	Office.	
	
According	to	Article	52	of	the	European	Patent	Convention,	for	an	invention	to	be	
patentable	within	the	European	patent	system,	there	are	three	main	criteria	that	must	be	
fulfilled.	First	of	all,	the	invention	must	be	“new”,	i.e.	it	cannot	have	been	known	at	the	time	
of	invention.	Secondly,	it	needs	to	involve	an	“inventive	step”.	This	requirement	is	
commonly	understood	to	mean	that	the	steps	taken	to	create	the	invention,	cannot	have	
been	obvious	to	a	person	skilled	in	the	art,	based	on	the	common	knowledge	in	the	field.		
	
The	final	of	the	main	criteria	is	that	the	invention	must	be	“susceptible	of	industrial	
application”.	This	is	defined	in	Article	57	EPC	as	being	able	to	“be	made	or	used	in	any	kind	
of	industry,	including	agriculture.”		
	
In	general,	the	lack	of	industrial	applicability	is	rarely	used	as	a	reason	to	oppose	or	reject	a	
patent.1	This	is	partly	caused	by	the	fact	that,	traditionally,	the	threshold	for	meeting	the	
requirement	has	been	considered	as	rather	low,	since	potential	applications	for	an	invention	
are	generally	fairly	obvious.2	Thus,	the	requirement	of	industrial	applicability	has	not	been	
regularly	assessed	by	the	Board	of	Appeal.	
	
In	the	past	few	decades,	however,	patent	applications	filed	for	inventions	in	the	
biotechnological	and	pharmaceutical	field	have	become	more	frequent,	as	techniques	in	the	
																																																						
1	See	Hector	MacQueen	et.al.,	Contemporary	Intellectual	Property:	Law	and	Policy,	2nd	
edition,	Oxford	2011	pp.	472-473.	
2	See	Robert	Fitt	and	Edward	Nodder,	“Setting	the	threshold	for	industrial	application:	the	
UK	diverges	from	Europe”,	Journal	of	Intellectual	Property	Law	&	Practice,	2010,	pp.	560-565	
(p.	560).	See	also	Bengt	Domeij,	Pharmaceutical	Patents	in	Europe,	Stockholm	2000	pp.	20-
22.	
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field	have	advanced3.	For	inventions	in	this	area,	the	industrial	application	is	not	always	
obvious,	and	newly	discovered	proteins	expressed	by	isolated	genes,	or	novel	chemical	
compounds	that	participate	in	biological	processes,	might	not	have	a	definitively	proven	
function	when	a	patent	application	is	filed.		
	
Especially	for	inventions	sought	to	be	used	in	disease	treatment,	months	or	years	of	in	vitro4	
and	in	vivo5	trials	may	be	necessary	to	conclusively	determine	how	the	substances	actually	
function	in	the	complex	biological	systems	they	are	assumed	to	act.	Parameters	like	efficacy	
or	side	effects,	might	not	be	determined	until	the	very	final	stages	of	the	development	
process.		
	
As	a	result	of	this,	patent	applications	are	routinely	filed	before	the	invention	has	been	
definitely	proven	to	function	as	desired.	It	is	therefore	of	great	importance	for	those	
developing	new	therapeutic	agents,	to	know	how	the	legislation	should	be	understood.		
	
For	the	most	part,	it	will	be	fairly	apparent	whether	or	not	an	invention	satisfies	the	
requirements	of	novelty	and	inventive	step.	For	these	requirements,	biotechnological	and	
pharmaceutical	inventions	are	in	any	case	not	vastly	different	from	those	in	other	fields.	The	
correct	understanding	of	the	requirement	of	industrial	application	is	therefore	particularly	
important,	as	it	effectively	dictates	how	early	in	the	development	process	a	patent	can	be	
granted.		
	 	
																																																						
3	According	to	the	EPO,	biotechnology	patents	have	for	the	”past	several	years”	consistently	
ranked	among	the	ten	largest	technical	fields	in	terms	of	patents	filed	(see	EPO’s	website	
(epo.org),	https://www.epo.org/news-issues/issues/biotechnology.html	(last	accessed	30	
May	2016)).		
4	In	vitro:	”biological	processes	and	reactions	occurring	in	(i)	cells	or	tissues	grown	in	culture	
or	(ii)	in	cell	extracts	or	synthetic	mixtures	of	cell	components”	(Eleanor	Lawrence	(ed.),	
Henderson’s	Dictionary	of	Biological	Terms,	11th	edition,	Harlow	1995).	
5	In	vivo:	”biological	processes	occurring	in	a	living	organism”	(Henderson’s	Dictionary	of	
Biological	Terms).	
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1.2 Questions	to	be	examined	in	this	paper	
	
In	defining	a	clear	interpretation	of	the	requirement	in	Article	57	EPC	for	industrial	
applicability,	there	are	several	questions	that	need	to	be	answered.	First	of	all,	how	the	
terms	“industry”	and	“made	or	used	in	industry”	should	be	understood	must	be	determined.	
Specifically,	the	question	here	is	whether	reproducibility	is	adequate,	or	if	something	more	
substantial	is	required.		
	
Secondly,	it	is	important	to	determine	what	degree	of	function	is	necessary	to	satisfy	the	
requirement.	Is	it,	for	example,	sufficient	that	the	claimed	substance	can	be	used	as	a	
research	tool,	or	is	it	necessary	to	disclose	a	biological	function,	e.g.	as	a	therapeutic	agent?	
	
Furthermore,	it	is	essential	to	determine	what	should	be	disclosed	in	the	patent	application	
to	support	the	claimed	industrial	application.	What	should,	for	example,	be	expected	in	
terms	of	proof?	Is	it	necessary	to	provide	experimental	evidence	conclusively	proving	the	
claimed	functions,	or	is	it	sufficient	that	the	purported	ways	of	exploiting	the	invention	are	
merely	plausible?	Are	results	from	computer-assisted	in	silico6	experiments	adequate	
evidence	to	support	an	assumed	function,	or	are	wet	biology7	experiments	compulsory?	
What	degree	of	quality	should	be	expected	from	the	disclosed	evidence,	and	how	much,	if	
any,	weight	can	be	placed	on	evidence	handed	in	after	the	filing	date?	
	
1.3 Method	
	
As	the	European	patent	system	is	based	on	the	“first	to	file”	principle,	answering	the	
questions	outlined	above	is	important	in	order	to	determine	at	what	time	the	filing	of	a	
patent	application	would	be	prudent.	The	goal	being	to	make	sure	that	sufficient	evidence	is	
presented	at	the	filing	date,	while	an	excessive	amount	of	time	is	not	spent	collecting	
evidence	that	is	not	required.		
	
																																																						
6	In	silico:	Simulations	done	using	computer-assisted	methods.	
7	Wet-biology	experiments:	A	collective	term	used	about	in	vitro	and	in	vivo	experiments.	
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The	reason	for	focusing	on	the	multilateral	rule	in	Article	57	EPC	rather	than	national	
legislation	is	simple:	most	patent	systems	on	the	national	level	in	Europe	are	largely,	if	not	
completely,	based	on	the	EPC.	The	interpretation	of	this	rule	will	therefore	be	applicable	
also	in	national	patent	systems.		
	
According	to	Article	31	(1)	of	the	Vienna	Convention,8	the	interpretation	of	a	treaty	should	
be	done	“in	accordance	with	the	ordinary	meaning	to	be	given	to	the	terms	of	the	treaty	in	
their	context	and	in	the	light	of	its	objective	and	purpose.”	While	the	Vienna	Convention	has	
not	been	ratified	by	all	member	states	of	the	European	Patent	Organisation,9	it	has	been	
established	that	this	convention	should	be	considered	a	codification	of	international	
customary	law10,	and	it	is	thus	a	basis	for	interpreting	conventions	such	as	the	EPC.		
	
The	literal	understanding	should	thus	be	the	foundation	for	an	interpretation	of	the	
requirements	that	follow	from	the	EPC.	It	is,	however,	not	given	that	the	interpretation	
should	be	solely	based	on	the	literal	understanding	of	the	terms.	Particularly	for	conventions	
whose	purpose	is	harmonisation	of	national	legal	systems,	the	practice	of	the	convention	
will	often	be	more	important.11	Where	the	practice	comes	from	executive	organs	tasked	
with	interpreting	the	convention,	as	is	the	case	for	EPO’s	Board	of	Appeal,	their	
understanding	of	the	terms	should	be	given	significant	weight.		
	
Additionally,	there	could	be	circumstances	dictating	that	less	importance	should	be	placed	
the	literal	understanding	of	the	terms	of	the	convention.	This	is	arguably	the	case	for	Article	
57	EPC	when	assessed	in	relation	to	inventions	in	the	pharmaceutical	and	biotechnological	
field.		
	
																																																						
8	Vienna	Convention	on	the	law	of	treaties,	23	May	1969.	
9	“The	European	Patent	Organisation	is	an	intergovernmental	organisation	that	was	set	up	
on	7	October	1977	on	the	basis	of	the	European	Patent	Convention	(EPC)”.	Cf.	EPO’s	website	
(epo.org),	https://www.epo.org/about-us/organisation.html	(last	accessed	31	May	2016).	
10	Morten	Ruud	and	Geir	Ulfstein,	Innføring	i	Folkerett,	4th	edition,	Oslo	2011	p.	81.	
11	See	Finn	Arnesen	and	Are	Stenvik,	Internasjonalisering	og	juridisk	metode:	særlig	om	EØS-
rettens	betydning	I	norsk	rett,	2nd	edition,	Oslo	2015	pp.	31-32.	
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Industrial	application	is	defined	only	in	broad	strokes,	and	includes	making	or	using	the	
invention	in	all	fields	of	industry.12	As	inventions	in	the	field	of	pharmaceuticals	and	
biotechnology	by	nature	are	quite	different	from	inventions	in	most	other	technical	fields,13	
a	literal	understanding	of	the	requirement	may	not	be	the	most	advantageous.	
	
While	the	practice	of	the	Board	of	Appeal	is	not	actually	binding	to	the	member	states,	nor	in	
other	cases	before	the	Board	themselves,	failure	to	conform	with	the	standards	formed	here,	
could	be	detrimental	to	the	harmonisation	of	the	European	patent	system.	Because	European	
patents	are	granted	by	the	EPO,	but	enforced	by	national	courts,	predictability	is	crucial.	If	
different	interpretations	of	the	legislation	are	assumed	in	the	different	states,	it	could	be	difficult	
for	applicants	to	determine	if	a	patent	granted	by	the	EPO	in	fact	will	offer	protection	in	the	
desired	member	states.	
	
The	consideration	of	legal	unity	therefore	dictates	that	practice	in	the	EPO	should	be	attributed	
considerable	weight,	even	when	interpreting	national	law.14	This,	held	together	with	the	fact	that	
there	are	not	many	examples	of	relevant	practice	on	the	national	level,	clearly	indicates	that	it	
will	be	most	sensible	to	base	an	analysis	of	the	requirement	of	industrial	applicability	on	the	
EPO’s	Board	of	Appeal	and	their	interpretation	of	Article	57	EPC.		
	
Consequently,	determining	how	the	rules	in	the	EPC	are	practiced	by	the	Board	of	Appeal,	
will	be	of	the	utmost	importance	when	defining	the	effect	of	the	requirements.		
	
	 	
																																																						
12	Phillip	W.	Grubb,	Patents	for	Chemicals,	Pharmaceuticals	and	Biotechnology,	4th	edition,	
Oxford	2004	p.	65.	
13	More	on	this	in	chapter	2.2	below.	
14	This	has	been	confirmed	by	several	national	courts.	See	e.g.	ruling	by	the	Norwegian	
Høyesterett	(Supreme	Court)	in	Rt.	2008	s.	1555	(Biomar)	paragraph	(51)	and	ruling	by	
English	Court	of	Appeal	in	[2010]	EWCA	Civ	33	(Eli	Lilly	and	Company	v	Human	Genome	
Sciences,	Inc.)	
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2 Background	
2.1 The	legal	framework	
	
Apart	from	several	international	agreements	on	patent	law,	like	TRIPS15	and	PCT,16	European	
patent	law	is	coloured	by	rules	issued	from	three	different	legal	spheres.17	First	of	all,	the	
European	Patent	Office	(EPO)	grants	patents	according	to	the	European	Patent	Convention	
(EPC),18	a	multilateral	treaty	with	38	member	states,	initiated	by	the	European	Council.	
Patents	granted	by	the	EPO	are,	however,	not	automatically	valid	in	all	member	states.	It	is	
up	to	the	applicant	to	define	in	the	application	the	states	in	which	he	wants	protection.	
National	patents	are	then	granted	and	enforced	in	the	specified	countries	provided	that	the	
EPO	approves	the	application.		
	
The	second	legal	sphere	is	made	up	of	the	national	patent	systems,	as	there	are	in	fact	slight	
variations	between	the	different	countries	in	legislation.	
	
Lastly,	the	European	Union	constructs	supranational	legislation,	attempting	to	form	a	
continuous	harmonisation	of	the	member	states’	national	patent	laws.	An	example	of	this,	is	
the	so-called	Biotech	Directive,19	which	obviously	is	relevant	for	inventions	in	the	
pharmaceutical	and	biotechnological	field.		
	
																																																						
15	Agreement	on	Trade-Related	Aspects	of	Intellectual	Property	Rights,	Annex	1C	of	the	
Marrakesh	Agreement	Establishing	the	World	Trade	Organization	(15	April	1994)	–	an	
international	agreement	setting	minimum	standards	for	intellectual	property	regulation.		
16	The	Patent	Cooperation	Treaty	(24	January	1970)	–	a	multilateral	patent	law	treaty,	
allowing	applicants	to	seek	patent	protection	in	148	member	countries	simultaneously.	
17	More	in	Timo	Minssen,	“När	anses	en	bioteknologisk	uppfinning	vara	komplett	och	
praktiskt	användbar?	–	Del	II	–	Om	senare	utveckling	kring	kravet	på	”industrial	application”	
och	”utility”	för	gen-	och	protein-relaterade	uppfinningar	i	USA	och	Europa”,	Nordiskt	
Immateriellt	Rettsskydd,	2008,	pp.	339-387	(pp.	340-341).	
18	The	European	Patent	Convention,	15	October	1973.	Currently,	the	15th	edition	is	in	effect.	
19	Directive	98/44/EC	of	the	European	Parliament	and	of	the	Council	of	6	July	1998	on	the	
legal	protection	of	biotechnological	inventions,	6	July	1998.	
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Additionally,	in	the	past	years,	efforts	have	been	made	to	implement	a	common,	multilateral	
patent	(as	opposed	to	one	organ	granting	patents	for	specified	countries).20	This	has	
resulted	in	the	Unified	Patent	Court,21	which	will	have	“exclusive	jurisdiction	for	litigation	
relating	to	European	patents	and	European	patents	with	unitary	effect”,22	and	will	enter	into	
force	as	soon	as	it	has	been	ratified	by	the	required	number	of	states.		
	
Because	there	are	several	different	patent	systems	currently	in	effect	in	Europe,	there	is	also	
a	large	potential	for	conflict.	One	of	the	most	actively	debated	subjects,	is	regarding	the	
correct	interpretation	of	the	requirement	for	industrial	applicability,	particularly	in	
assessment	of	patent	applications	for	gene	and	protein	related	inventions.23		
	
2.1.1 The	Biotech	Directive	
	
The	Biotech	Directive	has	had	a	central	role	in	the	discussion	of	how	the	requirement	of	
industrial	applicability	should	be	interpreted.	While	the	Directive	does	allow	for	patents	to	
be	granted	for	isolated	gene	sequences,	Article	5	(3)	prescribes	that	“[t]he	industrial	
application	of	a	sequence	or	a	partial	sequence	of	a	gene	must	be	disclosed	in	the	patent	
application.”	
	
It	follows	from	the	Biotech	Directive	that	gene	related	inventions	should	be	considered	on	
the	basis	of	the	same	criteria	as	all	other	inventions.	It	does,	however,	also	imply	that	the	
industrial	application	of	a	whole	or	partial	gene	sequence	will	never	be	considered	as	
obvious.	A	DNA	sequence	must	have	a	disclosed	function,	and	If	the	gene	sequence	is	shown	
to	encode	a	protein,	the	function	of	the	encoded	protein	must	also	be	provided.	If	several	
gene	sequences	are	claimed	in	the	application,	the	functions	of	all	sequences	must	be	
disclosed.	
																																																						
20	See	COM(2007)	165	-	Communication	from	the	Commission	to	the	European	Parliament	
and	the	Council	–	Enhancing	the	patent	system	in	Europe,	3	April	2007.	
21	The	Unified	Patent	Court	is	established	in	the	Agreement	on	a	Unified	Patent	Court	and	
Statute,	document	16351/12	of	11	January	2013.	
22	See	EPO’s	website	(epo.org)	https://www.epo.org/law-practice/unitary/patent-court.html	
(Last	accessed	28	May	2016).	
23	See	Minssen,	2008	p.	341.	
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While	the	Biotech	Directive	undoubtedly	is	important	in	the	clarification	of	legal	protection	
for	biotechnological	inventions,	it	is	not	absolutely	imperative	in	the	elucidation	of	how	the	
requirement	of	industrial	application	is	interpreted	by	the	EPO.	According	to	Rule	26	(1)	EPC,	
the	Directive	“shall	be	used	as	a	supplementary	means	of	interpretation”,	but	in	reality,	it	is	
rarely	mentioned	by	the	Board	of	Appeal.		
	
2.1.2 The	European	Patent	Convention	
	
Industrial	applicability	is	one	of	the	fundamental	requirements	in	European	patent	law,	and	
is	first	and	foremost	anchored	in	Article	52	(1)	EPC,	which	states	that	“European	patents	
shall	be	granted	for	all	inventions,	in	all	fields	of	technology,	provided	that	they	are	new,	
involve	an	inventive	step	and	are	susceptible	of	industrial	application”	(emphasis	by	
author).	
	
From	Article	57	EPC,	it	follows	that	an	invention	will	be	considered	“as	susceptible	of	
industrial	application	if	it	can	be	made	or	used	in	any	kind	of	industry,	including	agriculture”,	
and	Rule	42	(1)	(f)	EPC	states	that	the	description	of	the	patent	application	must	“indicate	
explicitly,	unless	it	is	obvious	from	the	description	or	the	nature	of	the	invention,	the	way	in	
which	the	invention	may	be	exploited	in	industry.”	
	
For	complete	and	partial	gene	sequences,	further	specification	is	found	in	Rule	29	(3)	EPC,	a	
literal	inclusion	of	Article	5	(3)	of	the	Biotech	Directive:	“[t]he	industrial	application	of	a	
sequence	or	a	partial	sequence	of	a	gene	must	be	disclosed	in	the	patent	application”.	
Hence,	it	follows	from	this	that	the	industrial	application	of	DNA	sequences	will	not	be	
considered	as	“obvious”.		
	
The	technical	Board	of	Appeal	has,	for	several	gene-	and	protein-related	inventions,	
acknowledged	industrial	applicability	according	to	Article	57	EPC,	especially	for	inventions	
that	have	proved	to	have	valuable	pharmaceutical	capabilities	directly	applicable	to	animal	
trials	within	the	pharmaceutical	industry.	For	the	most	part,	however,	the	specific	industrial	
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applications	have	been	so	plausible	and	clearly	stated	in	the	patent	applications,	that	the	
Board	neither	discussed	nor	mentioned	Rules	29	(3)	or	42	(1)	(f)	EPC.24	
	
Most	of	the	decisions	have	not,	therefore,	given	satisfying	answers	to	the	question	asked	
above.	However,	more	complex	cases	have	been	put	forward	for	the	Board	of	Appeal,	and	
there	are	consequently	several	examples	of	a	more	thorough	examination	of	the	
requirement	of	industrial	applicability.		
	
2.2 Biotechnological	and	pharmaceutical	inventions	
	
Since	before	morphine	was	extracted	from	the	opium	plant	and	marketed	for	pain	
management	in	the	early	1800s,	the	pharmaceutical	industry	has	played	a	key	role	in	the	
continued	advancement	of	human	health.	Were	it	not	for	the	prospects	of	financial	gain,	it	is	
highly	unlikely	that	the	treatment	of	disease	would	be	near	the	level	at	which	it	is	today.	
	
The	pharmaceutical	industry	has	a	collective	yearly	revenue	exceeding	$1000	billion.25	
Consequently,	there	are	undoubtedly	many	asking	questions	regarding	the	ethical	aspects	of	
pharmaceutical	patents,	arguing	that	therapeutic	agents	should	be	available	to	all,	and	that	
no	one	should	be	profiting	from	human	disease.26		
	
There	are,	however,	also	enormous	costs	associated	with	the	development	of	new	drugs.	
Large	teams	of	scientists	are	generally	needed,	and	prospective	therapeutic	agents	must	go	
through	extensive	testing	before	they	are	allowed	on	the	market.		
	
After	identifying	the	lead	compound,	i.e.	the	compound	performing	the	final	function	in	a	
biological	system,	work	starts	on	improving	the	potency,	reducing	toxicity	and	refining	
																																																						
24	See	e.g.	T	446/99	(Bordetella	toxin/AMGEN),	T	606/03	(Gene	trap/ARTEMIS),	T	1074/03	
(Soluble	peptides/IXSYS)	
25	See	Thomson	Reuters	website	(thomsonreuters.com),	
http://thomsonreuters.com/en/articles/2015/global-pharma-sales-reach-above-1-
trillion.html	(last	accessed	31	May	2016).	
26	See	e.g.	Sigrid	Sterckx,	”Can	drug	patents	be	morally	justified?”	Science	and	Engineering	
Ethics,	11	(1),	2005	pp.	81-92.	
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binding	specificity,	as	well	as	improving	the	duration	of	action	and	metabolic	and	
pharmacokinetic	patterns.27	According	to	a	study	done	by	the	Tufts	Center	for	the	Study	of	
Drug	Development,	the	average	cost	of	developing	a	drug	gaining	market	approval,	was	$2.6	
billion.	This	study	also	found	that	an	additional	§312	million	is	spent	on	further	testing	after	
approval	of	the	drug,	bringing	the	total	to	§2.9	billion.28	
	
Consequently,	there	is	great	importance	placed	on	having	intellectual	protection	and	
securing	the	investments	made	in	research	and	development.29	This	has	resulted	in	patents	
being	sought	at	every	step	from	inception	to	market	place,	which	could	lead	to	“dense	
thickets	of	intersecting,	overlapping,	and	cross-blocking	patents”,30	as	everyone	involved	is	
trying	to	gain	control	of	the	final	product.		
	
A	possible	consequence	of	this	has	been	described	as	the	“tragedy	of	the	anticommons”.	A	
situation	in	which	resources	are	prone	to	underuse	because	many	different	owners	have	a	
right	to	exclude	others	from	a	limited	resource.	If,	for	example,	all	receptors31	that	could	be	
used	in	screening	tests	were	controlled	by	different	owners,	collecting	the	necessary	licences	
to	screen	potential	drugs	against	these	receptors	would	be	near	impossible.	As	a	result,	
scientific	progress	could	decelerate,	as	less	promising	alternatives	would	be	pursued	if	they	
were	to	present	fewer	hurdles.32	
	
																																																						
27	See	George	de	Stevens,	”Lead	Structure	Discovery	and	Development”	in	Corwin	Hansch	
(ed.)	Comprehensive	Medicinal	Chemistry,	Oxford	1990,	pp.	261-284	(p.	266).	
28	Joseph	A.	DiMasi,	Henry	G.	Gabrowski	and	Ronald	W.	Hansen,	”Innovation	in	the	
pharmaceutical	industry:	New	estimates	of	R&D	costs”,	Journal	of	Health	Economics,	2016	
pp.	20-33	(p.	20).	
29	More	in	Philippe	Ducor,	”New	Drug	Discovery	Technologies	and	Patents”,	Rutgers	
Computers	&	Technology	Law	Journal,	1996	pp.	369-477	(p.	461).	
30	See	Thomas	D.	Kiley,	“Patents	on	Random	Complementary	DNA	Fragments?”	Science,	257	
(5072),	pp.	915-918	(p	916).	Also	Domeij,	2000,	pp.	19-38.	
31	Receptor	(here):	protein	to	which	a	signalling	molecule	such	as	a	neurotransmitter,	
hormone,	drug,	or	metabolite	binds	specifically	and	stimulates	a	particular	response	by	the	
cell	(Henderson’s	Dictionary	of	Biological	Terms).	
32	More	in	Michael	A.	Heller	and	Rebecca	S.	Eisenberg,	”Can	Patents	Deter	Innovation?	The	
Anticommons	in	Biomedical	Research”,	Science,	1998	pp.	698-701	(p.	699)	
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The	practice	of	filing	patent	applications	before	a	function	has	been	definitively	proven	is	
especially	evident	in	the	field	of	biotechnology.33	In	short,	biotechnology	is	the	use	of	living	
organisms	to	create	useful	products,	for	example	pharmaceuticals.	In	the	1970s,	scientists	
were	beginning	to	find	techniques	for	locating,	isolating,	preparing	and	studying	small	
segments	of	DNA.	As	the	techniques	for	cloning	DNA	improved,	the	field	of	proteomics34	
emerged,	enabling	the	study	of	all	genes	and	proteins	in	whole	cells.		
	
All	functions	occurring	in	a	biological	system	are	essentially	carried	out	by	proteins.	These	
proteins	are	expressed	from	the	genetic	information	stored	in	the	DNA.	Using	different	
biotechnological	methods,	scientists	are	able	to	identify	and	isolate	genes	and	proteins.	As	
the	areas	of	genomics35	and	proteomics	have	evolved,	large	libraries	of	genes	and	proteins	
isolated	from	different	organisms	(including	humans)	have	been	created.		This	allows	for	
comparison	of	newly	discovered	substances,	with	substances	that	have	known	functions,	
normally	by	carrying	out	some	sort	of	sequence	homology	assay.		
	
In	the	pharmaceutical	area,	biotechnology	is	first	of	all	used	to	identify	receptors	or	
enzymes36	involved	in	a	specific	process	related	to	a	disease,	and	then	finding	a	substance	
that	can	interfere	with	its	action.		
	
Furthermore,	several	diseases	are	effectively	treated	with	recombinant	proteins	produced	
using	biotechnological	methods.	A	few	examples	are:	Erythropoietin37	which	can	help	people	
																																																						
33	For	a	far	more	thorough	description	of	the	uses	and	methods	of	biotechnology,	see	See	
David	L.	Nelson	and	Michael	M.	Cox,	Lehninger	Principles	of	Biochemistry,	New	York	2013,	
pp.	435-436.	
34	Proteomics:	”Broadly,	the	study	of	the	protein	complement	of	a	cell	or	organism”	(glossary	
in	Nelson	and	Cox,	2013).	
35	Genomics:	”A	science	devoted	broadly	to	the	understanding	of	cellular	and	organism	
genomes”	(glossary	in	Nelson	and	Cox,	2013).	
36	Enzyme:	”any	of	a	large	and	diverse	group	of	(mainly)	proteins	that	function	as	biological	
catalysts	in	virtually	all	biochemical	reactions,	essential	in	all	cells,	different	enzymes	being	
highly	specific	for	a	particular	chemical	reaction	and	reactants”	(Henderson’s	Dictionary	of	
Biological	Terms).	
37	Erythropoietin:	”a	glycoprotein	hormone	produced	chiefly	by	the	kidney	and	which	
stimulates	the	final	differentiation	of	red	blood	cells	from	precursor	cells”	(Henderson’s	
Dictionary	of	Biological	Terms).	
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with	reduced	kidney	function	avoid	frequent	blood	transfusions;	insulin,38	which	is	used	in	
the	treatment	of	diabetes;	and	interleukins,39	used	in	the	treatment	of	HIV	infections,	cancer	
and	various	immune	deficiencies.		
	
As	the	use	of	biotechnology	and	recombinant	proteins40	is	becoming	more	and	more	
common	in	therapeutics,	the	practice	of	attempting	to	gain	patent	protection	at	the	earliest	
stages	of	research	and	development	is	also	increasingly	typical.	Patent	applications	are	
routinely	filed	for	partial	gene	sequences,	which	cannot	be	used	to	express	full	and	
functioning	proteins.41	Because	elucidating	the	biological	function	of	the	full	gene	and	the	
protein	it	encodes	is	the	most	expensive	step	in	the	process,	embarking	on	that	task	
becomes	even	more	unattractive	if	several	fragments	of	the	full	gene	are	already	patented.42		
	
While	the	potential	use	for	most	inventions	is	fairly	obvious,	this	is,	as	follows	from	the	
above,	often	not	the	case	for	inventions	in	the	field	of	pharmaceuticals	and	biotechnology.	
Whereas	all	identified	and	isolated	proteins	or	chemical	compounds	can	technically	be	
reproduced	(or	“made”),	the	endogenous	functions	of	such	substances	are	often	referred	to	
indistinctly,	and	based	on	similarity	with	substances	whose	functions	are	better	elucidated,	
as	extensive	research	is	required	for	these	to	be	uncovered.43		
	
																																																						
38	Insulin:	“a	polypeptide	hormone	produced	…	in	the	pancreas,	which	decreases	the	amount	
of	glucose	in	the	blood	by	promoting	glucose	uptake	by	cells	and	increasing	the	capacity	of	
the	liver	to	synthesize	glycogen”	(Henderson’s	Dictionary	of	Biological	Terms).	
39	Interleukins:	”diverse	group	of	proteins	produced	by	activated	macrophages	and	
lymphocytes	and	other	leukocytes	during	an	immune	response”	(Henderson’s	Dictionary	of	
Biological	Terms).		
40	Recombinant	protein:	”any	protein	protein	produced	from	a	recombinant	DNA	template.”	
Recombinant	DNA:	”DNA	produced	by	joining	together	in	vitro	genes	from	different	sources	
or	which	has	in	some	way	been	modified	in	vitro	to	introduce	novel	genetic	information”	
(Henderson’s	Dictionary	of	Biological	Terms).	
41	A	partial	gene	sequence	can,	in	reality,	only	function	as	a	probe	to	scan	for	the	full	gene.	It	
cannot	be	used	to	encode	a	full,	functioning	protein,	and	thus	will	not	cause	any	biological	
function.	Partial	gene	sequences	can,	however	be	useful	in	diagnosis	of	genetic	diseases.		
42	See	Domeij,	2000	p.	27.	
43	More	in	Denis	Schertenlieb,	”The	Patentability	and	Protection	of	DNA-based	Inventions	in	
the	EPO	and	the	European	Union”,	European	Intellectual	Property	Review,	2003	pp.	125-138	
(p.	128).	
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As	a	result	of	this,	clearly	defining	the	correct	interpretation	of	the	requirement	of	industrial	
applicability	is	particularly	important,	as	it	may	help	to	limit	the	ability	to	grant	patents	that	
in	reality	only	function	as	means	of	hindering	competitors	from	using	particular	substances	
in	their	research.	A	clear	understanding	of	the	requirement	will	also	aid	in	determining	when	
a	patent	application	should	be	filed.		
	
2.3 The	line	between	discovery	and	invention	
	
Discoveries	are,	according	to	Article	52	(2)	(a)	EPC,	excluded	from	patentability,	as	they	
“shall	not	be	regarded	as	inventions”.		
	
Since	the	potential	use	of	inventions	historically	has	been	quite	evident,	there	generally	has	
been	no	real	need	for	a	separate	evaluation	of	industrial	applicability.	Rather	than	explicitly	
evaluating	the	requirement	of	industrial	applicability,	the	question	has	therefore	largely	
been	whether	the	claimed	product	is	aimed	at	a	technical	result,	or	whether	it	is	merely	of	
an	abstract	and	intellectual	character,44	and	thus	falling	under	the	exclusions	listed	in	Article	
52	(2)	EPC.	The	nature	of	biotechnological	and	pharmaceutical	inventions,	however,	can	
often	cause	the	distinction	between	invention	and	nonpatentable	discoveries	to	become	
blurred.45	
	
The	line	between	discovery	and	invention	has	been	discussed	by	the	EPO	Board	of	Appeal	on	
several	occasions.	Discoveries	has	been	defined	as	“the	result	of	purely	intellectual	activity	
with	no	practical	or	or	technical	character”,	and	it	has	been	stated	that	the	question	of	
whether	the	claimed	substance	is	a	“mere	“discovery””	is	closely	linked	to	the	question	of	
whether	the	way	in	which	a	claimed	product	could	be	“exploited	in	industry”,	may	be	
derived	from	the	description,	or	if	the	described	product	is	“merely	an	interesting	research	
result	that	might	yield	a	yet	to	be	identified	industrial	application”.46	
	
																																																						
44	See	e.g.	T	22/85	(Document	abstracting	and	retrieving/IBM),	point	2	of	the	reasons.		
45	See	Schertenlieb,	2003	p.	127.	
46	T	338/00	(Multimeric	receptors/SALK	INSTITUTE),	point	2	of	the	reasons.		
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This	seems	to	mean	that	a	substance	should	be	considered	as	a	discovery	if	no	industrial	
application	can	be	derived	from	the	description	in	the	patent	application.	This	understanding	
is	also	assumed	in	literature.	According	to	Minssen,	for	example,	the	Board	of	Appeal	has	
implied	that	industrial	applicability	should	be	considered	as	an	integral	part	of	the	term	
“invention”.47	
	
To	be	considered	an	invention	and	not	merely	a	discovery,	a	claimed	product	must	therefore	
have	a	clear	practical	application	in	a	field	of	industry.	The	definition	of	the	requirement	in	
Article	57	EPC	is	consequently	incredibly	important.		
	
3 The	requirement	of	industrial	application	
3.1 “Industry”	
	
Article	57	EPC	reads	as	follows:	“[a]n	invention	shall	be	considered	as	susceptible	of	
industrial	application	if	it	can	be	made	or	used	in	any	kind	of	industry,	including	agriculture.”		
In	the	evaluation	of	the	requirement	of	industrial	application,	the	term	“industry”	is	
therefore	obviously	central.		
	
There	is,	however,	no	definition	of	the	term	“industry”	in	the	EPC	or	in	the	Biotech	Directive.	
Consequently,	it	is	necessary	to	look	at	the	case	law	in	order	to	determine	how	it	should	be	
interpreted.	
	
It	seems	quite	clear	from	practice	in	the	EPO’s	Board	of	Appeal,	that	the	term	“industry”	
should	be	interpreted	in	a	wide	sense.	This	follows	from	several	decisions,	but	is	most	often	
attributed	to	T	870/04	(BDP1	phosphatase/MAX	PLANCK).		
	
In	this	case,	the	claimed	substance	was	a	protein	called	brain	derived	phosphatase	1	(or	
BDP1).	The	application	suggested	that	the	claimed	protein	might	be	a	part	of	the	tyrosine	
																																																						
47	See	Minssen,	2008	p.	354.	
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phosphatase	family,48	and	that	it	therefore	would	be	involved	in	cellular	mechanisms,	such	
as	down-regulating	cell	proliferation,49	which	would	indicate	a	function	in	cancer	
treatment.50	
	
Examining	the	industrial	applicability	of	the	invention,	the	Board	states	that	“the	notion	of	
“industry”	has	to	be	interpreted	broadly	to	include	all	manufacturing,	extracting	and	
processing	activities	that	are	carried	out	continuously,	independently	and	for	financial	
(commercial)	gains”.51		
	
In	addition	to	being	confirmed	in	several	decisions	by	the	Board	of	Appeal,52	the	wide	
interpretation	of	“industry”	has	also	been	assumed	in	literature.	It	is,	for	example,	listed	by	
Minssen	as	the	first	of	six	principles	derived	from	practice	in	the	EPO.53	Additionally,	the	
interpretation	has	been	adopted	by	national	courts	,	as	in	the	case	of	Eli	Lily	Co.	vs.	Human	
Genome	Sciences.	Here,	Lord	Justice	Jacob	lists	the	broad	understanding	of	“industry”	as	
one	of	ten	guidelines	for	assessing	the	industrial	application	of	biotechnology	inventions.54	
	
																																																						
48	Phosphatases	are	enzymes	that	may	function	as	modulators	of	cellular	processes	by	
removing	a	phosphate	group	from	the	substrate	binding	to	it.	In	general,	dephosphorylation	
by	a	phosphatase	will	turn	a	cellular	funcion	off,	while	phosphorylation	by	the	corresponding	
kinase	will	turn	the	function	on.	Tyrosine	phosphatases	in	particular,	have	been	shown	to	be	
involved	in	controlling	signalling	pathwyas	in	a	number	of	fundamental	physiological	
processes	(see	Qing	Yang	et	al.,	“Cloning	and	Expression	of	PTP-PEST	a	novel,	human,	
nontransmembrane	protein	tyrosine	phosphatase”,	The	Journal	of	Biological	Chemistry,	
1993	pp.	6622-6628	(p.	6622),	referred	to	in	the	decision	as	”Document	D1”.	See	also	
Nicholas	K.	Tonks,	“Protein	tyrosine	phosphatases:	from	genes,	to	function,	to	disease”,	
Nature	Reviews	Molecular	Cell	Biology,	2006	pp.	833-846	(p.	833).	
49	Cell	proliferation:	“increase	[in	cell	number]	by	cell	division”	(Henderson’s	Dictionary	of	
Biological	Terms).	
50	T	870/04	(BDP1	phosphatase/MAX	PLANCK),	point	8	of	the	reasons.	See	also	the	
appellant’s	argument,	point	IX.	
51	Op.cit.,	point	2	of	the	reasons.	The	Board	also	refers	to	previous	decision	T	144/83	OJ	EPO,	
301,	point	5	of	the	reasons.		
52	See	e.g.	T	641/05	(GPCR-like	receptor/PHARMACIA),	point	2	of	the	reasons.	
53	Minssen,	2008	p.	375.	
54	[2010]	EWCA	Civ	33,	Eli	Lily	and	Company	v	Human	Genome	Sciences,	Inc.	See	also	Fitt	
and	Nodder,	2010,	Box	1	on	p.	564.	
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3.2 “Made	or	used	in	industry”	
	
Article	57	EPC	states	that	an	invention	will	be	“considered	as	susceptible	of	industrial	
application	if	it	can	be	made	or	used	in	any	kind	of	industry,	including	agriculture”	
(emphasis	by	author).	The	most	obvious	understanding	of	this,	is	that	so	long	as	the	
invention	can	be	reproduced	(“made”),	by	means	of	an	industrial	process,	it	will	be	
susceptible	of	industrial	application.	This	may	not,	however,	be	the	most	fortunate	way	of	
interpreting	the	term,	as	it	might	lead	to	a	system	in	which	patents	are	effectively	used	as	
“hunting	licences”,	reserving	entire	fields	of	research	for	the	patentees.55		
	
The	next	question	that	needs	to	be	examined,	therefore,	is	how	the	term	“can	be	made	or	
used	in	…	industry”	in	Article	57	EPC	should	be	understood.	This	is	a	question	that	has	been	
assessed	several	times	by	the	EPO,	and	the	answer	does	seem	to	be	well	established.		
	
In	ICOS/V28	seven	transmembrane	receptor,	one	of	few	cases	concerning	the	requirement	of	
industrial	applicability	that	have	been	assessed	by	the	EPO’s	opposition	division,	a	patent	
had	been	opposed	(among	other	reasons)	because	it	allegedly	did	not	fulfil	the	requirement	
of	Article	57	EPC.		
	
The	patent	covered	a	gene	sequence	and	the	protein	it	encoded,	V28	seven	transmembrane	
(V28	7TM)	receptor.	In	the	specification,	it	was	predicted	that	the	V28	protein	structure	
would	comprise	seven	hydrophobic	domains	separated	by	hydrophilic	domains	and	residues	
which	are	conserved	within	a	group	of	proteins	called	seven	transmembrane	(7TM)	
receptors.56	
																																																						
55	Minssen,	2008	p.	381.	
56	Seven	transmembrane	receptors,	or	G-protein	coupled	receptors	(GPCRs)	constitute	the	
largest,	most	ubiquitous	and	most	versatile	family	of	membrane	receptors	and	are	the	most	
common	target	of	therapeutic	drugs.	The	receptors	are	located	in	the	cell	membrane	and	
are,	as	the	name	suggests,	characterized	by	having	seven	distinct	membrane	spanning	
domains	and	coupled	with	guanine	nucleotide-binding	proteins	(G-proteins).	When	a	ligand	
binds	to	the	receptor,	it	causes	a	conformational	change	in	the	molecule	and	the	G-protein	is	
activated,	making	it	a	molecular	“switch”.	See	e.g.	Nina	Wettschureck	and	Stefan	
Offermanns,	“Mammalian	G	Proteins	and	Their	Cell	Type	Specific	Functions”,	Physiological	
Reviews,	2005	pp.	1159-1204	(pp.	1160,	1163).		
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The	specification	also	stated	that	host	cells	expressing	products	of	the	V28	7TM	gene	would	
be	useful	in	the	large	scale	production	of	V28	7TM	protein,	and	that	antibodies57	reacting	
with	V28	7TM	protein	would	be	useful	in	complexes	for	immunisation	to	generate	anti-
idiotypic	antibodies,58	purifying	V28	peptides	and	for	identifying	cells	producing	V28	protein.	
	
It	was	suggested	that	ligands59	(antibodies,	agonists60	and	antagonists61)	of	V28	protein	
could	be	useful	in	modulating	binding	reactions	involved	in	immunological	and/or	
inflammatory	processes	in	vivo.	No	antibodies,	agonists	or	antagonists	were,	however,	
disclosed	in	the	application,	and	any	involvement	of	the	protein	in	such	processes	was	not	
demonstrated.62	
	
The	patentee	argued	that	because	the	application	disclosed	how	to	make,	and	proposed	
functions	for,	the	claimed	V28	protein,	the	requirement	for	industrial	application	must	be	
satisfied.		
	
The	opposition	division	did	not	agree,	and	stated	that	the	requirement	would	not	be	fulfilled	
just	because	“the	specification	shows	that	V28	can	be	made	and	can	be	used.”63	Thus	it	
seems	that	the	term	“made	or	used	…	in	industry”	should	not	be	understood	literally,	an	
interpretation	which	is	also	adopted	in	several	decisions	by	the	technical	Board	of	Appeal.		
																																																						
57	Antibody:	a	serum	protein	which	is	formed	in	response	to	an	antigenic	stimulus	and	reacts	
specifically	with	that	antigen;	antigen:	a	substance	which	elicits	the	synthesis	of	an	antibody	
with	which	it	specifically	reacts	(Emery’s	Elements	of	Medical	Genetics).	
58	An	anti-idiotypic	antibody	can	bind	to	other	antibody	molecules,	inhibiting	their	binding	to	
their	respective	antigens	(more	in	Ying	Pan,	Stacieann	C.	Yuhasz	and	L.	Mario	Amzel,	“Anti-
idiotypic	antibodies:	biological	function	and	structural	studies”,	Federation	of	American	
Societies	for	Experimental	Biology	Journal,	1995	pp.	43-49	(p.	43).	
59	Ligand:	“any	molecule	that	binds	specifically	to	another	molecule.	Examples	are	a	
hormone	binding	to	its	receptor,	an	inhibitor	binding	to	an	enzyme,	oxygen	binding	to	
haemoglobin,	and	antigen	binding	to	an	antibody”	(Henderson’s	Dictionary	of	Biological	
Terms).	
60	Agonist	(here):	”substance	responsible	for	triggering	a	response	in	a	cell,	such	as	a	
hormone,	neurotransmitter,	etc.”	(Henderson’s	Dictionary	of	Biological	Terms).	
61	Antagonist	(here):	”any	substance	that	counteracts	the	effect	of	a	hormone,	
neurotransmitter,	drug,	etc.”	(Henderson’s	Dictionary	of	Biological	Terms).	
62	OJ	EPO	2002,	6	(ICOS/V28	seven	transmembrane	receptor),	point	9	(i).	
63	op.cit.,	point	9.	
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In	T	870/04	(BDP1	phosphatase/MAX	PLANCK),64	the	application	did	not,	according	to	the	
Board,	disclose	sufficient	evidence	to	make	the	proposed	functions	plausible.	While	there	
was	little	doubt	of	the	involvement	of	tyrosine	phosphatases	in	down-regulating	their	
corresponding	kinases	and	their	catalytic	activity	in	cell	proliferation,	the	suggested	
functions	of	the	claimed	protein	were	largely	based	on	the	known	functions	of	similar	
proteins.		
	
Eventually,	it	was	concluded	that	the	only	probable	function	disclosed,	was	the	ability	to	
produce	the	protein	itself.	It	was	stated	that:	
	
“The	requirement	of	Article	57	EPC	that	the	invention	“can	be	made	or	used”	in	at	
least	one	field	of	industrial	activity	emphasizes	that	a	“practical”	application	of	the	
invention	has	to	be	disclosed.	Merely	because	a	substance	(here:	a	polypeptide)	
could	be	produced	in	some	ways	does	not	necessarily	mean	that	this	requirement	is	
fulfilled,	unless	there	is	also	some	profitable	use	for	which	the	substance	can	be	
employed”	(emphasis	by	the	Board).65	
	
This	then	confirms	the	interpretation	in	ICOS/seven	transmembrane	receptor,	that	
something	more	substantial	is	required	from	the	invention	than	it	simply	being	able	to	be	
made	and	used.	
	
In	the	assessment	of	industrial	applicability	in	T	898/05	(Hematopoietic	
receptor/ZYMOGENETICS),	the	Board	states	that	even	if	the	structure	of	a	product	is	given,	
and	it	therefore	can	be	reproduced,	a	patent	cannot	be	granted	if	the	function	is	
“undetermined	or	obscure	or	only	vaguely	indicated”.66	If	patents	were	granted	in	such	
situations,	the	patentee	would	gain	“unjustified	control	over	others	who	are	actively	
investigating	in	that	area	and	who	might	eventually	find	actual	ways	to	exploit	it”.67	
	
																																																						
64	See	above	in	chapter	3.1.	
65	T	870/04	(BDP1	phosphatase/MAX	PLANCK),	point	4	of	the	reasons.		
66	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	point	7	of	the	reasons.		
67	Ibid.	
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Further	specification	of	the	term	can	be	found	in	T	338/00	(Multimeric	receptors/SALK	
INSTITUTE).	Here,	the	patent	application	covered	a	receptor	reportedly	belonging	to	the	
steroid/thyroid	hormone	receptor	superfamily,68	purported	to	form	heterodimeric	
receptors69	with	other	members	of	the	superfamily.	These	heterodimeric	receptors	would	in	
turn	function	as	modulators	of	“suitable	expression	systems”.70	
	
The	core	of	the	discussion	regarding	the	industrial	application	is	whether	the	way	in	which	
the	invention	may	be	exploited	in	industry,	may	be	derived	from	the	description,	or	if	it	what	
presented	is	“merely	an	interesting	research	result	that	might	yield	a	yet	to	be	identified	
industrial	application”.71	The	Board	did	find	that	the	applicant	had	provided	ample	evidence	
of	not	only	the	cooperative	interactions	forming	the	heterodimeric	receptors,	but	also	of	the	
use	of	these	receptors	for	“modulating	suitable	transcription	expression	systems”,	and	their	
relevance	in	several	biological	processes.72	
	
It	is	stated	that	“[t]he	activities	and	product	disclosed	in	the	application	are	not	aimed	at	an	
abstract	or	intellectual	character	but	at	a	direct	technical	result	that	may	clearly	be	applied	
in	an	industrial	activity”.73	
	
Thus,	it	follows	from	this	decision	that	in	order	for	an	invention	to	be	susceptible	of	
industrial	application,	it	must	have	a	concrete,	technical	use	that	can	be	employed	in	a	field	
of	industry.	If	the	proposed	functions	are	too	broad	and	abstract,	industrial	applicability	
cannot	be	acknowledged.		
	
																																																						
68	The	steroid/thyroid	hormone	receptor	superfamily	is	a	family	of	proteins	binding	to	
steroid	or	thyroid	hormones.	Such	receptor	proteins	have	great	therapeutic	implications,	as	
they	could	be	used	in	treatment	of	a	variety	of	hormone	related	diseases	(see	Pengxiang	
Huang,	Vikas	Chandra	and	Fraydoon	Rastinejad,	“Structural	Overview	of	the	Nuclear	
Receptor	Superfamily:	Insights	into	Physiology	and	Therapeutics”,	Annual	Review	of	
Physiology,	2010	pp.	247-272).	
69	Heterodimeric	receptors:	a	receptor	composed	of	two	different	protein	subunits	(see	
Henderson’s	Dictionary	of	Biological	Terms).	
70	T	338/00	(Multimeric	receptors/SALK	INSTITUTE),	point	3	of	the	reasons.		
71	Op.cit.,	point	2	of	the	reasons.		
72	T	338/00	(Multimeric	receptors/SALK	INSTITUTE),	point	3	of	the	reasons.	
73	Ibid.	
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3.3 “Function”	
	
It	has	been	established	that	the	patent	application	must	disclose	a	practical	way	to	exploit	
the	invention.	The	core	of	the	assessment	of	the	requirement	in	Article	57	EPC,	particularly	
as	it	pertains	to	inventions	in	the	field	of	pharmaceuticals	and	biotechnology,	thus	appears	
to	be	what	function	the	claimed	substance	performs.	Consequently,	it	must	also	be	
determined	what	should	be	expected	from	the	disclosed	function.		
	
As	mentioned	above,	it	follows	from	T	338/00	(Multimeric	receptors/SALK	INSTITUTE)	that	
the	invention	must	have	a	concrete,	technical	result	that	may	clearly	be	applied	in	an	
industrial	activity.74	
	
This	is	further	specified	in	T	870/04	(BDP1	phosphatase/MAX	PLANCK),	where	the	Board	
states:	
“although	the	present	application	described	a	product	(a	polypeptide),	means	and	
methods	for	making	it,	and	its	prospective	use	thereof	for	basic	science	activities,	it	
identifies	no	practical	way	of	exploiting	it	in	at	least	one	field	of	industrial	activity.	In	
this	respect,	it	is	considered	that	a	vague	and	speculative	indication	of	possible	
objectives	that	might	or	might	not	be	achievable	by	carrying	out	further	research	
with	the	tool	as	described	is	not	sufficient	for	fulfilment	of	the	requirement	of	
industrial	applicability.	The	purpose	of	granting	a	patent	is	not	to	reserve	an	
unexplored	field	of	research	for	an	applicant.”75	
	
The	Board	concedes	that	there	is	no	doubt	that	the	protein	would	be	usable	as	a	research	
tool	in	the	further	investigation	of	the	role	phosphatases	and	kinases	play	in	cellular	
signalling	systems,	and	perhaps	also	for	diagnostic	or	therapeutic	purposes.	The	application	
does,	however,	leave	it	to	the	skilled	reader	to	uncover	these	functions	by	carrying	out	
extensive	research	programmes.		
	
																																																						
74	T	338/00	(Multimeric	receptors/SALK	INSTITUTE),	point	3	of	the	reasons.		
75	T	870/04	(BDP1	phosphatase/MAX	PLANCK),	point	21	of	the	reasons.	
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Moreover,	the	Board	emphasises	that	the	application	must	disclose	“some	profitable	use	for	
which	the	substance	can	be	employed”.76	This	goes	a	long	way	to	define	what	is	required	of	
the	function,	as	the	use	of	the	invention	must	be	translatable	to	commercial	gain.		
	
Consequently,	it	will	often	not	be	adequate	that	the	invention	can	be	used	as	a	research	
tool.	Rather,	it	must	have	concrete	function	that	can	be	employed	for	e.g.	therapeutic	or	
diagnostic	purposes.	That	the	invention	can	be	used	to	carry	out	research	on	itself	is	not	
sufficient	to	satisfy	the	requirement.		
	
Thus,	the	conclusion	in	T	870/04	(BDP1	phosphatase/MAX	PLANCK),	is	that	even	though	the	
application	disclosed	a	protein,	how	to	isolate	and	reproduce	this	protein	and	prospective	
uses	in	research	activities,	“it	identifies	no	practical	way	of	exploiting	it	in	at	least	one	field	of	
industrial	activity”.77	Because	it	was	not	at	all	certain	that	the	objectives	given	in	the	
application	would	be	achievable	by	using	the	invention	as	a	research	tool,	the	requirement	
of	industrial	application	was	not	satisfied.78	It	is	also	stated	that:	
	
“In	cases	where	a	substance,	naturally	occurring	in	the	human	body,	is	identified,	and	
possibly	also	structurally	characterised	and	made	available	through	some	method,	
but	either	its	function	is	not	known	or	it	is	complex	and	incompletely	understood,	
and	no	disease	or	condition	has	yet	been	identified	as	being	attributable	to	an	excess	
or	deficiency	of	the	substance,	and	no	other	practical	use	is	suggested	for	the	
substance,	then	industrial	applicability	cannot	be	acknowledged.”79		
	
What	can	be	derived	from	this	decision,	is	that	a	function	that	can	be	directly	put	to	
“profitable	use”	must	be	disclosed	in	the	application.	If	the	disclosed	functions	are	based	on	
speculations,	and	further	research	is	required	to	confirm	an	actual	industrial	application,	the	
requirement	of	Article	57	EPC	is	not	fulfilled.			
																																																						
76	T	870/04	(BDP1	phosphatase/MAX	PLANCK),	point	6	of	the	reasons.	
77	Op.cit.,	point	21	of	the	reasons.		
78	See	Rainer	Moufang	“Patentability	of	pharmaceutical	innovations”	in	Josef	Drexl	and	Nari	
Lee	(eds.),	Pharmaceutical	Innovation,	Competition	and	Patent	Law,	Cheltenham	2013	pp.	
80-81.	
79	T	870/04	(BDP1	phosphatase/MAX	PLANCK),	point	6	of	the	reasons.	
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This	interpretation	is	confirmed	in	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	
where	the	claimed	invention	is	a	DNA	sequence	encoding	a	protein	called	Zcytor1.	The	
application	describes	Zcytor1	as	a	“cytokine80	receptor	with	a	role	in	proliferation,	
differentiation81	and	activation	of	immune	cells”.	It	was	also	suggested	that	the	protein	
might	play	a	role	in	the	development	and	regulation	of	immune	responses.		
	
The	Board	makes	it	clear	that	a	disclosed	function	is	essential	for	determining	industrial	
applicability	of	a	newly	discovered	protein,	because	“the	function	is	the	gateway	to	
understanding	the	concrete	benefits	which	may	derive	from	exploiting	the	invention	
industrially”.82	
	
Referring	to	T	870/04	(BDP1	phosphatase/MAX	PLANCK)	and	the	term	“profitable	use”	as	a	
threshold	for	adequate	function,	the	Board	states	that	rather	than	understanding	
“commercial	gain”	as	a	potential	for	economic	profit,	it	should	be	“understood	in	the	wider	
sense	that	the	invention	claimed	must	have	such	a	sound	and	concrete	technical	basis	that	
the	skilled	person	can	recognise	that	its	contribution	to	the	art	could	lead	to	practical	
exploitation	in	industry”.83	The	expression	“profitable	use”	could	therefore	be	understood	as	
“immediate,	concrete	benefit”.84	
	
The	requirement	is	further	clarified	as	the	Board	states	that	“a	product	which	is	definitely	
described	and	plausibly	shown	to	be	usable,	e.g.	to	cure	a	rare	or	orphan	disease,	might	be	
considered	to	have	a	profitable	use	of	concrete	benefit,	irrespective	of	whether	it	is	actually	
intended	for	the	pursuit	of	any	trade	at	all”.85	Products	of	such	nature	will	there	fore	meet	
the	requirement	of	industrial	application.		
	
																																																						
80	Cytokine:	“any	protein	factor	such	as	a	growth	factor,	which	is	a	product	of	a	cell	and	
which	affects	the	growth	and	division,	or	other	functions,	of	other	cells”	(Henderson’s	
Dictionary	of	Biological	Terms).		
81	Cell	differentiation:	“the	development	of	cells	with	specialized	structure	and	function	from	
unspecialized	precursor	cells”	(Henderson’s	Dictionary	of	Biological	Terms).	
82	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	point	20	of	the	reasons.		
83	Op.cit.,	point	5	of	the	reasons.		
84	Op.cit.,	point	6	of	the	reasons.		
85	Op.cit.,	point	8	of	the	reasons.	
	 25	
It	is	clear	from	this,	that	“profitable	use”	should	be	interpreted	as	“beneficial	use”,	so	that	it	
relates	to	a	concrete	benefit	to	society,	rather	than	simply	an	economic	benefit	for	the	
patentee.		
	
For	the	invention	in	question,	the	Board	found	that	although	the	details	of	the	biochemical	
activity	and	cellular	function	were	not	disclosed	in	the	application,	the	therapeutic	
treatments	that	could	be	derived	directly	from	the	functions	suggested	by	results	from	
computer-assisted	experiments	“cannot	be	considered	to	be	so	“vaguely	defined”	that	they	
do	not	suggest	any	therapeutic	or	diagnostic	use.”86	Furthermore,	the	Board	found	that	the	
therapeutic	functions	proposed	by	the	application	were	plausibly	related	to	the	disclosed	
structure	of	the	protein.		
	
The	protein	was	therefore	not	just	a	simple	research	tool	that	could	only	be	used	to	do	
further	research	in	the	quest	for	an	industrial	application.		
	
It	seems	clear	that	the	main	point	in	the	assessment	of	industrial	applicability	should	be	
whether	or	not	the	technical	contribution	is	useful	to	the	point	that	society	may	reap	from	it	
an	immediate	benefit.	If	a	naturally	occurring	substance	known	to	have	a	function	of	major	
importance	to	human	health	is	identified	and	isolated,	this	will	immediately	indicate	a	
practical	use	and	therefore	also	industrial	applicability.		
	
It	does,	however,	follow	from	T	604/04	(PF4A	receptors/GENENTECH),	that	a	product	does	
not	need	to	be	immediately	or	directly	available	for	use	in	the	treatment	of	diseases	for	it	to	
be	deemed	as	displaying	an	“immediate	concrete	benefit”.		
	
In	this	case,	the	application	covered	the	identification	of	various	DNA	sequences	encoding	
several	polypeptides	functioning	as	receptors	for	the	PF4A	superfamily	of	cytokines.	
	
																																																						
86	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	point	31	of	the	reasons.	
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It	follows	from	this	decision	that	“the	skilled	person”	should	be	able	to	reproduce	“without	
undue	burden”	the	claimed	invention,	on	the	basis	of	what	is	disclosed	in	the	patent	
specification.87	
	
The	Board	does	state	that	the	“technical	data”	for	some	of	the	claimed	polypeptides	“fall	
somewhat	short”	of	fulfilling	the	criteria	defined	in	T	870/04	(BDP1	phosphatase/MAX	
PLANCK),88	as	no	evidence	was	disclosed	as	to	which	ligands	would	bind	to	the	claimed	
proteins.	However,	it	is	specified,	that	“the	common	general	knowledge	at	the	priority	date”	
has	to	be	taken	into	account.89	
	
Looking	to	existing	research	therefore,	the	Board	found	clear	evidence	to	support	that	the	
PF4A	family	of	cytokines	at	the	priority	date	were	attractive	agents	for	development	of	new	
pharmaceuticals,	as	research	indicated	that	inhibition	of	their	activity	could	improve	wound	
healing	and	tissue	repair.90	
	
Hence,	the	Board	concluded	that	the	PF4A	family	of	chemokines91	at	the	priority	date	were	
“considered	not	only	to	be	interesting	in	fundamental	research	but	also	as	important	for	the	
pharmaceutical	industry	irrespective	of	whether	or	not	their	role	had	been	clearly	defined”92	
(emphasis	by	the	Board).	It	was	also	clear	from	the	prior	art	that	the	function	of	chemokines	
is	determined	through	the	receptors	they	bind	to,	and	it	was	therefore	concluded	that	the	
receptors	had	to	be	equally	important.	As	a	result,	the	requirement	of	industrial	applicability	
had	to	be	satisfied.93	
	
																																																						
87	T	604/04	(PF4A	receptors/GENENTECH),	point	22	of	the	reasons.		
88	Cf.	T	870/04	(BDP1	phosphatase/MAX	PLANCK),	point	6	
89	T	604/04	(PF4A	receptors/GENENTECH),	point	15	of	the	reasons.	
90	Op.cit.,	point	17	of	the	reasons,	referencing	Mark	Y.	Stoeckle	and	Kimberly	A.	Barker,	“Two	
Burgeoning	Families	of	Platelet	Factor	4-Related	Proteins:	Mediators	of	the	Inflammatory	
Response”,	The	New	Biologist,	1990	pp.	313-323.	
91	PF4A	proteins	are	members	of	the	cytokine	subcategory	chemokines,	which	are	involved	
in	inflammatory	response.	See	Stoeckle	and	Barker,	1990	p.	313.	
92	T	604/04	(PF4A	receptors/GENENTECH),	point	18	of	the	reasons.		
93	Ibid.	
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Thus,	it	follows	that	if	a	substance	is	considered	to	be	of	great	importance	for	the	
development	of	new	therapeutic	agents,	it	might	be	permissible	not	to	have	clearly	defined	
its	function	at	the	time	the	patent	application	is	filed.94	
	
3.4 Disclosure	
3.4.1 Proof	of	function	
3.4.1.1 Standard	of	proof	
	
In	order	to	establish	the	earliest	point	at	which	an	applicant	can	reasonably	expect	a	patent	
to	be	granted,	it	is	imperative	to	determine	what	evidence	must	be	disclosed	in	the	
application	
	
When	determining	the	evidence	that	is	required	for	industrial	applicability	to	be	
acknowledged,	it	must	first	be	decided	what	is	the	actual	standard	of	proof.	Is	it	sufficient	
that	the	proposed	application	is	plausible	when	looking	at	the	prior	art	and	common	general	
knowledge,	or	must	the	function	be	demonstrated	through	experiments?	
	
The	patent	application	in	T	1329/04	(Factor-9/JOHN	HOPKINS)	covered	the	polypeptide	
growth	differentiating	factor-9	(GDF-9),	and	DNA	sequences	encoding	proteins	having		
GDF-9	activity.	These	proteins	were	assumed	to	be	part	of	the	transforming	growth		
factor-β	(TGF-β)	family,	a	group	of	proteins	that	are	involved	in	cell	growth	and	
differentiation,	and	thus	have	significant	therapeutic	implications.95	
																																																						
94	See	Moufang,	2013	p.	81.	
95	Drugs	affecting	TGF-β	signalling	are	used	in	treatment	of	e.g.	heart	disease	(see	Lim,	H.	
and	Zhu,	Y.	Z.,	“Role	of	transforming	growth	factor-beta	in	the	progression	of	heart	failure”,	
Cellular	and	Molecular	Life	Sciences,	2006	pp.	2584-2596),	cancer	(see	Gerard	C.	Blobe,	
William	P.	Schiermann	and	Harvey	F.	Lodish,	“Role	of	Transforming	Growth	Factor	β	in	
Human	Disease”,	New	England	Journal	of	Medicine,	2000	pp.	1350-1358	(pp.	1351-1354)),	
obesity.	Davina	Wu	et	al.,	“Eosinophils	Sustain	Adipose	Alternatively	Activated	Macrophages	
Associated	with	Glucose	Homeostasis”,	Science,	2011	pp.	243-247),	and	Multiple	Sclerosis	
(see	Ramesh	K.	Selvaraj	and	Terrence	L.	Geiger,	“Mitigation	of	Experimental	Allergic	
Encephalomyelitis	by	TGF-β	Induced	Foxp3+Regulatory	T	Lymphocytes	through	the	Induction	
of	Anergy	and	Infectious	Tolerance”,	Journal	of	Immunology,	2008	pp.	2830-2838).	Recent	
research	has	also	indicated	that	TGF-β	signalling	might	be	involved	in	Alzheimer’s	disease	
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It	is	stated	in	the	decision	that	the	question	to	be	investigated	is	“whether	or	not	it	is	
plausible	that	the	molecule	…	constitutes	a	further	member	of	the	TGF-β	superfamily”96	
(emphasis	by	author).	Furthermore,	the	Board	also	states	that	“[t]he	definition	of	an	
invention	as	being	a	contribution	to	the	art,	i.e.	as	solving	a	technical	problem	and	not	
merely	putting	forward	one,	requires	that	it	is	at	least	made	plausible	by	the	disclosure	in	
the	application	that	its	teaching	solves	indeed	the	problem	it	purports	to	solve”.97		
	
Plausibility	is	also	the	threshold	assumed	in	T	604/04	(PF4A	receptors/GENENTECH).	Here	
the	Board,	with	regards	to	the	claimed	proteins,	states	that	“[t]he	first	question	which	arises	
is	whether	or	not	these	are	bona	fide	solutions	to	the	above	defined	problem”.98	
Subsequently	the	decision	in	T	1329/04	(Factor-9/JOHN	HOPKINS)99	is	cited,	before	the	
Board	states	that	“there	is	no	absolute	certainty	that	the	polypeptides	of	Figures	4	and	5	
[the	claimed	proteins]	are	receptors	for	members	of	the	PF4A	family	of	cytokines	–	to	which	
IL-8	belongs	–	yet,	in	the	board’s	judgment,	the	above	mentioned	structural	features	make	it	
plausible	that	this	is	indeed	the	case.”100	
	
That	the	structures	of	the	disclosed	proteins	make	it	plausible	that	they	are	in	fact	receptors	
for	PF4A	cytokines,	seems	to	be	sufficient,	as	the	Board	continues	onto	answering	the	
question	of	whether	or	not	the	claimed	proteins	may	be	considered	“inventive”.		
	
Plausibility	as	the	standard	of	proof	is	confirmed	in	T	898/05	(Hematopoietic	
receptor/ZYMOGENETICS),	where	industrial	applicability	was	also	acknowledged	by	the	
Board	of	Appeal.	In	this	decision,	it	is	stated	that	because	no	evidence	from	the	prior	art	
suggested	that	the	proposed	functions	of	the	Zcytor1	protein	would	not	be	directly	linked	to	
																																																						
(see	Walter	Swardfager	et	al.,	“A	Meta-Analysis	of	Cytokines	in	Alzheimer’s	Disease”,	
Biological	Psychiatry,	2010	pp.	930-941).	
96	T	1329/04	(Factor-9/JOHN	HOPKINS),	point	6	of	the	reasons.		
97	Op.cit.,	point	12	of	the	reasons.		
98	T	604/04	(PF4A	receptors/GENENTECH),	point	5	of	the	reasons.	
99	T	1329/04	(Factor-9/JOHN	HOPKINS),	point	12	of	the	reasons.	
100	T	604/04	(PF4A	receptors/GENENTECH),	point	6	of	the	reasons	
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its	structure,	“the	assumption	(or	“educated	guess”)	made	in	the	patent	application	is	
plausible.”101	
	
The	Board	goes	on	to	say	that	the	claimed	receptor	protein	“cannot	be	seen	as	a	mere	tool	
for	research	undertaken	for	its	own	sake	or	in	the	quest	to	provide	industrially	applicable	
matter,	but	rather	as	a	product	with	a	plausible	application	in	an	industrial	(medico-
pharmaceutical)	activity.”102	
	
Thus,	it	follows	that	if	a	substance	is	considered	to	be	of	great	importance	for	the	
advancement	of	new	therapeutic	agents,	it	might	be	permissible	not	to	have	clearly	defined	
its	function	at	the	time	the	patent	application	is	filed.	
	
3.4.1.2 Required	evidence	
	
According	to	literature,	establishing	the	subjective	“at	least	plausible”	test,	sprouted	many	
new	questions.	A	central	one	of	which,	is	when	the	EPO	considers	an	invention	as	sufficiently	
complete	to	be	able	to	carry	out	an	examination	of	the	fundamental	criteria	for	
patentability.103	This	is,	of	course,	closely	linked	to	questions	that	are	essential	in	order	to	
determine	the	most	opportune	time	to	file	a	patent	application	in	the	European	“first	to	file”	
system	The	first	of	which	being	what	data	must	be	provided	to	sufficiently	prove	that	the	
requirement	is	satisfied.			
	
Article	83	EPC	states	that	“[t]he	European	patent	application	shall	disclose	the	invention	in	a	
manner	sufficiently	clear	and	complete	for	it	to	be	carried	out	by	a	person	skilled	in	the	art.”	
This	requirement	is	routinely	assessed	by	the	EPO,	and	often	in	relation	to	the	assessment	of	
Article	57	EPC.	
	
	 	
																																																						
101	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	point	27	of	the	reasons.		
102	Op.cit.,	point	31	of	the	reasons.		
103	See	Minssen	2008,	p.	359	
	 30	
According	to	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	function	of	a	protein	can	
be	at	three	different	levels:		
	
“i)	the	biochemical	activity	of	the	protein	(protease,	endonuclease,	ion	channel	or	
pump,	etc.),	i.e.	its	molecular	function;	ii),	the	function	of	the	protein	in	cellular	
processes	(apoptosis,	secretion	pathway,	etc.),	i.e.	its	cellular	function;	and	iii)	the	
influence	of	those	cellular	processes	within	a	multicellular	organism,	i.e.	in	a	general	
and	more	complex	network	with	a	multicellular	organism	(cancer,	inflammation,	
immune	responses,	etc.),	this	being	its	biological	function	in	a	broad	sense.”104	
	
The	biological	function	and	the	concrete	benefits	that	followed	from	it,	were	in	this	case	
clearly	disclosed.105	Even	though	the	details	of	the	biochemical	activity	and	cellular	function	
of	the	protein	had	not	been	explained	in	the	application,	they	could	be	directly	derived	from	
the	disclosed	experiment	results.		
	
It	thus	follows	from	this	decision	that	the	disclosure	of	function	on	one	of	the	three	levels,	
might	in	itself	be	sufficient	to	satisfy	the	requirement	of	industrial	application,	even	if	the	
other	levels	of	function	have	not	been	elucidated.		
	
Perhaps	the	most	pressing	question	regarding	the	evidence	required	to	support	the	claimed	
industrial	application,	is	whether	computer-assisted	sequence	data	is	sufficient,	or	if	
traditional	wet-lab	experiments	are	necessary.	
	
The	use	of	computer-assisted	methods	is	becoming	more	common	in	research,	and	the	
importance	of	traditional	wet-lab	experiments	may	be	declining,	at	least	in	the	early	stages	
of	research	and	development.	There	will,	of	course,	always	be	a	need	for	in	vitro	and	in	vivo	
testing	of	new	pharmaceutical	inventions	before	they	are	brought	to	market	in	order	to	
ensure	that	they	are	safe	and	have	an	appropriate	efficacy.	The	actual	functionality,	
																																																						
104	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	point	29	of	the	reasons.	
105	Ibid.	
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however,	may	conceivably	be	determined	almost	exclusively	by	computer	simulation	in	the	
not	too	distant	future.106	
	
It	seems	clear	from	the	case	law,	however,	that	there	is	still	some	reluctance	to	acknowledge	
industrial	applicability	when	the	proposed	functions	are	based	solely	on	in	silico	analyses.	
	
In	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	the	Board	concedes	that	the	
structural	properties	of	a	protein	may	be	derived	from	the	gene	sequence	encoding	it,	but	
points	out	that	the	function	cannot	necessarily	be	determined	in	this	manner.	It	is	stated	
that	“[t]he	fact	that	the	putative	function	of	the	Zcytor1	receptor	was	assigned	in	the	
examples	based	on	computer-assisted	methods,	rather	than	on	the	basis	of	traditional	wet-
lab	techniques,	does	not	mean	that	it	has	to	be	automatically	disregarded	or	excluded	from	
a	careful	and	critical	examination”.107	The	Board	goes	on	to	say	that	the	“probative	value”	of	
evidence	stemming	from	computer-assisted	methods,	must	be	“examined	on	a	case-by-case	
basis	regarding	the	nature	of	the	invention	and	the	prior	art	relating	hereto”.108	
	
Thus,	it	follows	that	although	in	silico	experiments	certainly	are	permissible	as	evidence	
supporting	a	purported	function,	the	weight	carried	by	such	experiments	must	be	
determined	considering	the	nature	of	the	invention	(e.g.	the	complexity	of	the	biological	
processes	it	is	thought	to	affect	or	the	importance	of	identifying	new	substances	in	the	field)	
and	the	prior	art	relating	to	the	area	of	the	invention.	If,	for	example,	the	prior	art	makes	it	
clear	that	structure	and	functionality	are	closely	related,	a	high	degree	of	sequence	
homology	with	a	substance	of	known	function	will	indicate	that	the	claimed	substance	also	
will	be	able	to	perform	these	functions.109	
																																																						
106	See	Han	van	de	Watermeemd	and	Eric	Gifford,	“ADMET	in	silico	modelling:	towards	
prediction	paradise?”	Nature	Reviews	Drug	Discovery,2003	pp.	192-204.	Also:	Kelly	Rae	Chi,	
“Revolution	dawning	in	cardiotoxicity	testing”,	Nature	Reviews	Drug	Discovery,	2013	pp.	
565-567.	
107	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	point	22	of	the	reasons.	
108	Ibid.	
109	Ibid.	See	also	T	1165/06	(IL-17	related	polypeptide/SCHERING),	point	25	of	the	reasons:	
“The	sequence	information	provided	in	the	application	with	respect	to	the	presence	in	IL-
174	of	the	characteristic	cysteine	spacing	of	the	IL-17	cytokine	family	makes	it	plausible	that	
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It	also	seems	that	the	threshold	for	regarding	in	silico	results	as	sufficient	is	lowered	when	
the	substance	is	thought	to	be	of	major	importance	for	research.	This	is	the	case	in	T	604/04	
(PF4A	receptors/GENENTECH),	where	the	Board	found	that	the	importance	of	simply	
discovering	new	members	of	the	PF4A	chemokine	receptor	family	was	considered	to	be	
more	important	than	to	actually	discover	their	specific	functions.110	
	
A	higher	threshold	for	computer-assisted	homology	studies	supporting	industrial	
applicability	is	set	in	T641/05	(GPCR-like	receptor/PHARMACIA).	The	application	in	this	case	
covered	several	slightly	modified	clones	of	CEGPCR1,	a	GPCR-like	receptor111	identified	in	the	
invertebrate	Caenorhabditis	elegans,	that	shared	89.6%	sequence	identity	with	AC7.1,	a	
previously	known	GPCR-like	receptor.	This	high	degree	of	homology	did,	according	to	the	
applicant,	indicate	that	the	claimed	clones	would	have	the	same	applications	as	AC7.1,	these	
being	antibody	and	ligand	binding	and	mediation	of	signal	transduction.112		
	
The	Board	noted	that	the	evidence	of	function	was	based	only	on	sequence	homology	
analyses	done	with	CEGPCR1,	and	that	the	protein	was	described	as	“tending	to	fall”	into	a	
group	of	known	invertebrate	neuropeptide	receptors	“closely	related	to	a	vertebrate	family	
of	receptors”.	There	was	also	no	distinction	made	between	the	reference	sequence	of	
CEGPCR1	and	the	specific	sequences	of	the	clones,113	and	it	was	well	known	that	various	
GPCRs	could	have	vastly	different	properties;	some	might	not	even	have	any	activity	at	all.114	
	
Because	the	patent	was	sought	for	several	genes	and	their	corresponding	polypeptides,	and	
their	functions	were	based,	solely	or	for	the	most	part,	on	sequence	homology	studies,	such	
																																																						
this	polypeptide	may	belong	to	this	family	and	have	biological	activities	similar	to	those	of	
the	other	family	members	known	at	the	filing	date”.	
110	T	604/04	(PF4A	receptors/GENENTECH),	points	17	and	18	of	the	reasons.	
111	G-Protein	Coupled	Receptors	(GPCR)	are	transmembrane	receptors	that	sense	molecules	
outside	the	cell	and	activate	inside	signal	transduction	pathways	and	cellular	responses,	
through	the	(guanine	nucleotide-binding	proteins)	G-proteins,	which	act	as	molecular	
switches	(See	Nelson	and	Cox,	2013	pp.	435-436).	
112	T	641/05	(GPCR-like	receptor/PHARMACIA),	point	XIII	of	the	summary	of	facts	and	
submissions.		
113	Op.cit.,	point	10	of	the	reasons.		
114	Op.cit.,	point	11	of	the	reasons.		
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studies	should	be	provided	for	each	of	the	claimed	sequences.	This	is	especially	true	where	
minute	alterations	in	structure	can	lead	to	large	changes	in	functionality.115	
	
The	Board	found	that	no	concrete	information	about	applicable	functions	could	be	derived	
directly	from	the	description	or	the	prior	art,	and	in	conclusion	stated	that	“[a]lthough,	
under	certain	conditions,	the	board	is	well	prepared	–	following	the	case-by-case	approach	
adopted	in	decision	T	898/05	(supra)	–	to	acknowledge	a	possible	function	based	on	
computer	assisted	methods	…	in	the	present	case	the	probative	value	of	these	(sequence	
homology)	methods	is	completely	lacking	for	the	reasons	set	out	above.”116	
	
It	is	clear	then,	that	computer-assisted	in	silico	experiments	can	be	considered	as	sufficient	
evidence	for	industrial	applicability	to	be	acknowledged.	This	is,	however,	dependent	upon	
the	nature	of	the	invention	and	the	probative	value	of	the	results,	which	must	be	
determined	on	a	case-by-case	basis.	
	
3.4.1.3 Required	quality	of	the	submitted	evidence	
3.4.1.3.1 Required	quality	of	evidence	in	general	
	
As	it	has	been	established	what	evidence	must	be	submitted	to	support	the	purported	
industrial	applications	of	an	invention,	the	level	of	quality	expected	from	this	evidence	must	
also	be	determined.	Is	it,	for	example,	sufficient	to	plausibly	demonstrate	analogy	between	
the	claimed	product	and	a	substance	of	known	function?	And	if	such	analogy	is	sufficiently	
proven,	will	it	be	adequate	to	provide	a	list	of	functions	performed	by	the	homologous	
substance?	
	
It	is	abundantly	clear	from	the	case	law	that	a	way	of	exploiting	the	invention	must	be	
disclosed	in	the	patent	application.	As	seen	above	in	3.4.1.2,	however,	it	follows	from	T	
898/05	(Hematopoietic	receptor/ZYMOGENETICS),	that	it	may	be	sufficient	to	provide	a	
function	at	one	of	three	levels	(molecular,	cellular	or	biological)	in	order	to	satisfy	the	
requirement	of	Article	57	EPC.		
																																																						
115	T	641/05	(GPCR-like	receptor/PHARMACIA),	point	11	of	the	reasons.	
116	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	point	14	of	the	reasons.		
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In	this	case,	the	board	found	that	the	biological	function	was	clearly	disclosed.	The	applicant	
had	performed	tests	showing	that	agonist	ligands	of	the	claimed	receptor	caused	cell-
mediated	immunity	and	lymphocyte	proliferation,	while	antagonist	ligands	caused	
suppression	of	the	immune	system.117	Even	though	the	molecular	and	cellular	mechanisms	
behind	this	were	not	provided	in	the	results,	the	Board	found	that	they	could	be	derived	
from	the	submitted	evidence.		
	
It	can	be	inferred	from	this	decision	that	corresponding	ligands	should	be	disclosed	if	the	
claimed	substance	is	a	receptor	and	vice	versa.	If	function	on	a	molecular,	cellular	and/or	
biological	level	can	be	derived	from	the	interactions	between	ligands	and	receptors,	this	will	
then	be	sufficient	to	satisfy	the	requirement	of	industrial	applicability.			
	
This	also	follows	from	the	decision	in	ICOS/Seven	transmembrane	receptor,	where	the	
opposition	division	found	that	the	requirement	for	industrial	application	was	not	satisfied,	
because	the	uses	proposed	in	the	specification	were	based	on	a	purported	function	of	the	
V28	protein	as	a	receptor.	This	function	was,	however,	“not	sufficiently	disclosed	in	the	
specification”.118	It	is	stated	that	even	if	a	putative	function	of	a	protein	is	disclosed	along	
with	a	way	of	verifying	this	function,	this	is	not	“necessarily	adequate	to	sufficiently	disclose	
the	function	of	the	protein.”119	When	the	claimed	protein	is	a	purported	receptor,	a	ligand	
capable	of	binding	to	the	receptor	must	also	be	disclosed.	Because	no	ligand	was	disclosed	
in	the	application,	proposed	uses	were	considered	“speculative,	ie	are	not	specific,	
substantial	and	credible	and	as	such	are	not	considered	industrial	applications.”120	
	
It	seems	clear,	therefore,	that	not	only	is	it	necessary	to	disclose	a	way	in	which	the	
invention	may	be	exploited	in	industry,	but	the	disclosed	application	must	also	be	based	on	
sound,	scientific	evidence.	Mere	speculation	will	not	be	sufficient	to	satisfy	the	requirement	
of	industrial	application.		
	
																																																						
117	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	point	31	of	the	reasons.	
118	ICOS/Seven	transmembrane	receptor,	point	9	(i).	
119	Op.cit.,	headnote	
120	Op.cit.,	point	9	(i)	
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Disclosing	a	clearly	defined	function	is	not	always	absolutely	necessary,	however.	As	seen	
above	in	3.3	the	Board	in	T	604/04	(PF4A	receptors/GENENTECH)	found	that	if	the	claimed	
product	is	of	such	significance	to	the	advancement	of	research	in	the	field	that	the	mere	
identification	is	considered	more	important	than	actually	determining	a	function.121	There	
can,	however,	be	little	to	no	doubt	that	the	claimed	substance	in	fact	has	the	purported	
features.		
	
In	T	18/09	(Neutrokine	alpha/HUMAN	GENOME	SERVICES),	the	application	in	question	was	
for	a	gene	sequence	encoding	Neutrokine-α,	a	member	of	the	TNF	ligand	superfamily.122	The	
patent	had	been	contested,	on	grounds	of,	inter	alia,	lack	of	industrial	applicability.		
	
The	patent	application	relied,	for	the	most	part,	on	tissue	expression	data	to	prove	that	
Neutrokine-α	was	in	fact	a	member	of	the	TNF	ligand	superfamily,	as	other	members	were	
known	to	be	expressed	in	lymphomas.	The	specification	also	provided	an	undisputed	
structural	identification	of	Neutrokine-α	as	a	member	of	the	TNF	ligand	superfamily	and	
disclosed	further	relevant	technical	data,	fully	in	line	with	the	properties	expected	of	a	
member	of	this	superfamily.	In	particular,	the	specification	disclosed	the	tissue	distribution	
of	Neutrokine-α	mRNA123	expression	using	the	gene	sequence	encoding	the	protein	as	a	
cDNA124	probe,	and	reported	the	expression	of	Neutrokine-α	in	activated	T-cells.125,	126	
																																																						
121	T	604/04	(PF4A	receptors/GENENTECH),	points	17-18.	
122	The	TNF	(Tumor	Necrosis	Factor)	family,	is	a	group	of	cytokines	that	can	cause	apoptosis	
(programmed	cell	death).	The	TNF	ligand	superfamily	is	a	family	of	ligands	that	bind	to	and	
consequently	affect	TNF	receptors.	Known	to	be	expressed	in	lymphomas,	and	are	therefore	
widely	used	in	the	diagnosis	and	treatment	of	lymphomas	(see	Hans	Jürgen	Gruss	and	
Steven	K.	Dower,	“Tumor	Necrosis	Factor	Ligand	Superfamily:	Involvement	in	the	Pathology	
of	Malignant	Lymphomas”,	Blood,	85	(12),	1995	pp.	3378-3403).	
123	mRNA:	messenger	RNA,	an	intermediary,	carrying	genetic	information	from	one	or	a	few	
genes	to	a	ribosome,	where	the	corresponding	proteins	can	be	synthesised	(see	Nelson	and	
Cox,	2013	p.	273).	
124	cDNA:	complementary	DNA,	a	DNA	strand	complementary	to	an	mRNA	template,	used	to	
prepare	synthetic	DNA	(see	Nelson	and	Cox,	2013	p.	273).	
125	T	18/09	(Neutrokine	alpha/HUMAN	GENOME	SERVICES),	point	24	of	the	reasons.		
126	T-cell:	”a	type	of	small	antigen-specific	lymphocyte	originating	in	thymus	(in	mammals)	
and	present	in	secondary	lymphoid	tissues	(e.g.	lymph	nodes,	spleen)	and	blood,	and	which	
is	involved	in	cellular	immune	reactions	and	aiding	the	production	of	antibodies”	
(Henderson’s	Dictionary	of	Biological	Terms).	
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The	Board	states	that	because	it	was	known	from	the	prior	art	that	a	common	feature	of	all	
members	of	the	TNF	ligand	superfamily,	is	expression	in	activated	T-cells,	and	ability	to	co-
stimulate	T-cell	proliferation,	“no	serious	doubts	can	be	cast	on	this	explicit	additional	
information.	Nor	can	this	information	be	taken	as	a	mere	theoretical	or	purely	hypothetical	
assumption.”127	
	
Although	there	was	no	doubt	that	members	of	the	TNF	superfamily	may	have	many	varied	
functions,	and	that	further	research	definitely	would	be	needed	to	fully	explicate	all	
functions	of	the	protein,	all	the	functions	enumerated	for	members	of	the	superfamily	were,	
according	to	the	Board,	actually	quite	likely.128	
	
It	follows	from	the	decisions	cited	above,	that	it	is	not	absolutely	necessary	to	provide	
experimental	proof	of	a	way	in	which	the	invention	can	be	exploited	in	industry	at	the	time	
the	application	is	filed.	Where	the	invention	is	conclusively	proven	(e.g.	by	structural	
homology	or	tissue	expression	data)	to	be	a	member	of	a	family	of	substances	that,	with	few	
exceptions,	are	known	to	have	therapeutic	effects,	and	it	is	probable	that	this	is	the	case	
also	for	the	claimed,	a	list	of	functions	linked	to	other	members	of	the	family	may	be	
sufficient.		
	
3.4.1.3.2 Required	quality	of	in	silico	evidence		
	
As	mentioned	above,	in	silico	experiments	are	rapidly	becoming	more	prevalent	in	
pharmaceutical	research	and	development.	And	while	it	is	clear	that	such	evidence	may	be	
accepted	as	the	main	proof	supporting	the	purported	functions	of	an	invention,	it	must	still	
be	determined	what	quality	requirements	are	set	for	evidence	stemming	from	computer-
assisted	analyses.	
	
It	follows	from	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS)	that	the	“probative	
value”	of	in	silico	evidence	must	be	assessed	on	a	“case-by-case	basis”.	The	Board	points	out	
that	the	case	law	suggests	that	a	protein	could	be	considered	as	being	industrially	applicable	
																																																						
127	T	18/09	(Neutrokine	alpha/HUMAN	GENOME	SERVICES),	point	24	of	the	reasons.	
128	Op.cit.,	point	23	of	the	reasons.	
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despite	the	patent	application	not	disclosing	sufficient	experimental	data.	The	Board	refers	
to	T	338/00	(Multimeric	receptor/SALK	INSTITUTE)	and	T	604/04	(PF4A	
receptors/GENENTECH),	where	the	industrial	applicability	could	be	derived	from	the	
description	when	seen	in	combination	with	the	general	knowledge	in	the	field.129	
	
It	is	noted	in	the	decision	that	the	claims,	through	use	of	computer-assisted	in	silico	
analyses,	disclosed	several	features	related	to	the	structure	of	the	protein,	that	indicated	
Zcytor1	being	a	part	of	the	hematopoietic	receptor	family130	and	the	wider	cytokine	receptor	
superfamily.	It	is	also	pointed	out	that	the	application	showed	large	scale	Zcytor1	expression	
in	immune	cells	and	that	the	therapeutic	applications	were	described	for	agonist	and	
antagonist	ligands	of	the	protein.	These	data	indicated	important	functions	involved	in	the	
immune	system,	and	possible	applications	in	the	development	of	therapeutic	inventions.131		
	
The	Board	found	that	because	the	structural	features	discovered	by	computer-assisted	
methods	could	be	linked	to	the	purported	functions,	and	evidence	showed	that	the	protein	
was	expressed	in	various	human	tissue,	it	was	very	likely	that	the	protein	indeed	was	a	
member	of	the	hematopoietic	receptor	family.	It	is	stated	that:	
	
“Although	the	details	of	the	biochemical	activity	and	the	cellular	function	of	the	
Zcytor1	receptor	have	not	been	elucidated	in	the	application,	the	(therapeutic)	
treatments	directly	derivable	from	the	biological	function	identified	by	the	computer-
assisted	method	cannot	be	considered	to	be	so	“vaguely	defined”	that	they	do	not	
suggest	any	therapeutic	or	diagnostic	use.	On	the	contrary,	the	treatments	referred	
to	in	the	application	are	specifically	in	relation	to	the	function	plausibly	attributed	to	
the	molecule,	and	are	in	the	areas	of	rheumatoid	arthritis,	multiple	sclerosis,	
diabetes	mellitus,	etc.	In	this	respect,	this	case	differs	from	that	of	decision	T	870/04	
																																																						
129	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	points	11	and	12	of	the	reasons.		
130	Hematopoietic	receptor:	receptors	involved	in	haematopoiesis,	the	development	of	
blood	cells	from	stem	cells	(Henderson’s	Dictionary	of	Biological	Terms).	
131	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	point	21	of	the	reasons.		
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(supra)	where	no	clear	role	for	the	claimed	molecule	was	identified	(cf.	point	10	
supra).”132	
	
The	application	did	not	disclose	the	percentage	of	identity	with	other	members	of	the	
family,	or	describe	specific	ligands.	Nevertheless,	the	Board	found	that	because	earlier	
research	indicated	that	members	of	the	haematopoietic	receptor	family	generally	had	
analogous	biological	features	and	functions,133		it	was	highly	probable	that	the	Zcytor1	
receptor	would	perform	similar	functions.		
	
The	opposite	conclusion	was	reached	in	T	1452/06	(Serine	protease/BAYER).	Here,	the	
application	covered	a	DNA	sequence	encoding	a	protein	related	to	mouse	epithin,134	
“expected	to	be	useful	for	the	same	purposes	as	previously	identified	proteases	…	
particularly	useful	for	treating	cancer	and	COPD”.135,136	The	basis	for	these	therapeutic	
indications,	was	the	assumed	role	of	the	serine	protease	activity	of	the	protein	in	the	
degradation	of	the	extracellular	matrix.	The	Board	quickly	concluded	that	in	order	for	the	
“claimed	subject-matter	to	fulfil	the	requirement	of	industrial	application	the	purported	
serine	protease	activity	of	the	polypeptide	…	is	essential.”137	
	
However,	the	Board	could	not	see	that	any	experimental	evidence	had	been	presented	in	
the	application	that	showed	the	protein	having	serine	protease	activity.	Neither	was	there	
evidence	to	support	that	the	screening	methods	and	therapeutic	indications	based	on	the	
purported	activity	could	in	fact	be	achieved	with	the	claimed	protein.	According	to	the	
Board,	the	evidence	presented	was	largely	speculative	and	based	on	computer-assisted	
																																																						
132	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS,	point	31	of	the	reasons	
133	Op.cit.,	point	27	of	the	reasons.		
134	Epithin	is	a	serine	protease,	a	class	of	enzymes	that	cleave	peptide	bonds	in	proteins,	and	
are	involved	in	several	biological	functions,	including	digestion,	immune	responses	and	
reproduction.	Epithin	has	also	been	shown	to	be	involved	in	various	cancer	cell	lines,	and	is	
therefore	interesting	in	cancer	treatment	research.	(See	Hyo	S.	Lee	et	al.,	“Epithin,	a	target	
of	transforming	growth	factor-beta	signalling,	mediates	epithelial-mesenchymal	transition”,	
Biochemical	and	Biophysical	Research	Communications,	2010	pp.	553-569	(p.	553)).	
135	COPD:	Chronic	obstructive	pulmonary	disease.	
136	T	1452/06	(Serine	protease/BAYER),	point	3	of	the	reasons,	referencing	page	12,	lines	10	
to	12	of	patent	application	01964964.9	–	Human	epithin-like	serine	protease).		
137	T	1452/06	(Serine	protease/BAYER),	point	3	of	the	reasons.	
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homology	studies	of	mouse	epithin,	which	was	only	a	“putative	serine	protease”	(emphasis	
by	the	Board).138	Regarding	the	presence	of	both	serine	and	histidine	active	site	signatures	
(which,	according	to	a	study	presented	in	the	application,	made	the	probability	of	the	
protein	being	a	member	of	the	trypsin	family	of	serine	proteases	100%),	it	is	stated	that	
“[w]hereas	the	presence	of	these	signatures	might	well	be	necessary	for	serine	protease	
activity,	these	signatures	are	certainly	not	sufficient	for	a	polypeptide	to	be	functionally	
active”	(emphasis	by	the	Board).139	It	was	highlighted	that	the	disclosed	polynucleotide	was	
only	a	partial	sequence	of	a	gene	that	was	similar	to	that	encoding	epithin,	and	that	not	all	
members	of	the	serine	protease	family	have	the	same	biological	functions.	Consequently,	
the	Board	concluded	that	the	computer-assisted	studies	were	based	on	information	far	too	
incomplete	to	allow	credible	assumptions	to	be	made	regarding	the	function	of	the	
protein.140		
	
This	was	also	the	conclusion	in	T	1109/10	(Hydroxylases/LEXICON).	In	this	case,	the	
application	covered	four	proteins	assumed	to	function	as	tryptophan	hydroxylases,141	
“involved	in	a	rate-limiting	step	in	the	biosynthesis	of	neurologically	active	compounds,	
including	serotonin”.142	Because	of	this	assumed	function,	the	claimed	proteins	were	
expected	to	be	useful	in	identification	and	development	of	pharmaceuticals	for	behaviour	
modification.143	
	
The	Board	found	that	the	description	was	severely	lacking	in	evidence	to	support	the	
claimed	function	of	the	proteins.	It	is	stated	that	“[t]he	fact	that	two	proteins	share	a	certain	
structural	similarity	does	not	automatically	imply	that	they	have	the	same	enzymatic	
activity.”144	
																																																						
138	T	1452/06	(Serine	protease/BAYER),	point	7	of	the	reasons.		
139	Op.cit.,	point	8	of	the	reasons.		
140	Op.cit.,	point	17	of	the	reasons.		
141	Hydroxylases	are	enzymes	involved	in	hydroxylation,	a	chemical	process	which	introduces	
a	hydroxyl	group	into	an	organic	compound.	This	process	can	convert	lipophilic	compounds	
into	hydrophilic	products,	and	is	thus	important	in	detoxification,	as	hydrophilic	compounds	
are	more	easily	secreted	(see	e.g.	Nelson	and	Cox,	2013	pp.	798-799).	
142	T	1109/10	(Hydroxylases/LEXICON),	point	3.1	of	the	reasons.	
143	Op.cit.,	point	3.2	of	the	reasons.		
144	Op.cit.,	point	4	of	the	reasons.		
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The	proposed	functions	were	based	solely	on	amino	acid	sequence	comparison,	and	the	
closest	prior	art	had	not	presented	any	correlation	between	protein	structure	and	
tryptophan	hydroxylase	activity.	A	high	degree	of	homology	did	therefore	not	give	sufficient	
reason	to	assume	that	the	claimed	protein	would	possess	the	same	functions	as	other	
hydroxylases.145	As	a	result,	industrial	applicability	could	not	be	acknowledged.		
	
In	T	1165/06	(IL-17	related	polypeptide/SCHERING),	industrial	applicability	was	
acknowledged	on	the	basis	of	sequence	homology	studies.	In	this	case,	the	claim	covered	a	
polypeptide,	IL-174,	that	showed	significant	sequence	homology	with	the	cytokine	CTLA-8	
(IL-17),	which	has	been	shown	to	function	in	controlling	physiology,	development	and	
differentiation	of	mammalian	cells.	It	was	therefore	assumed	that	the	claimed	proteins	
would	be	useful	in	mediating	a	variety	of	responses	characteristic	of	cytokine	signalling.146		
	
In	a	very	brief	assessment	of	the	requirement	of	industrial	applicability,	the	Board	states	that	
because	the	sequence	information	clearly	showed	the	presence	of	markers	characteristic	of	
the	IL-17	cytokine	family,	it	was	“plausible	that	this	polypeptide	may	belong	to	this	family	
and	have	biological	activities	similar	to	this	of	the	other	family	members”.147	This,	held	
together	with	the	confirming	post-published	documentation	supplied	by	the	applicant,	
meant	that	the	requirement	in	Article	57	EPC	was	satisfied.		
	
Regarding	an	actual	quantification	of	the	quality	required,	there	are	few	examples	of	any	
more	or	less	exact	threshold	in	the	case	law.148	According	to	a	survey	done	by	the	Trilateral	
																																																						
145	T	1109/10	(Hydroxylases/LEXICON),	point	3.2	of	the	reasons.		
146	The	IL-17	family	of	cytokines	has	been	shown	to	be	especially	important	in	host	defence	
and	inflammatory	diseases	(see	Wei	Jin	and	Chen	Dong,	“IL-17	cytokines	in	immunity	and	
inflammation”,	Emerging	Microbes	and	Infections,	2013	pp.	1-5).	
147	T	1165/06	(IL-17	related	polypeptide/SCHERING),	point	25	of	the	reasons.	
148	See	e.g.	T	604/04	(PF4A	receptors/GENENTECH),	where	85%	homology	is	accepted	as	
sufficient	(point	10),	T	1329/04	(Factor-9/JOHN	HOPKINS)	where	it	is	stated	that	members	of	
a	given	subgroup	of	the	TGF-β	superfamily	had	between	70%	and	90%	homology	(point	8),	
and	T	1109/10	(Hydroxylases/LEXICON),	where	71%	homology	was	not	sufficient	to	establish	
that	a	new	human	tryptophan	hydroxylase	had	been	identified	(point	4).	
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Co-operation,149	however,	homology	data	will	not	be	accepted	by	the	EPO	if	the	homology	is	
below	55%,	while	80%	could	be	sufficient	if	the	assay	is	done	across	the	whole	sequence	and	
not	just	a	restricted	region.150	
So,	although	there	is	no	doubt	that	the	EPO	does	allow	results	from	computer	assisted	in	
silico	studies	as	the	main	evidence	in	support	of	industrial	application,	there	cannot	be	much	
doubt	surrounding	the	value	of	the	evidence.	First	of	all,	it	seems	that	there	needs	to	be	a	
clear	and	definite	correlation	between	the	structure	of	the	protein	and	its	function.	If	this	is	
evident	from	the	general	knowledge	in	the	field	and	the	prior	art,	a	high	degree	of	homology	
with	a	protein	with	a	known	function	may	be	sufficient.	If	the	family	of	protein	the	invention	
fits	into	is	known	to	have	many	varied	functions,	further	proof	of	function	on	a	cellular	or	
biological	level	may	be	required.		
	
Also,	if	the	claimed	protein	is	thought	to	function	in	complex	systems	where	many	other	
substances	are	operative	and	affecting	each	other,	more	substantial	evidence	may	be	
required.	In	such	systems,	it	is	less	likely	that	the	protein	will	carry	out	the	exact	function	
that	the	structure	indicates,	as	it	may	e.g.	act	synergistically	with	one	or	more	of	the	other	
substances	in	the	system.		
	
3.4.2 Weight	of	evidence	submitted	after	the	filing	date	
	
According	to	Rule	42	(1)	(f)	EPC,	the	“way	in	which	the	invention	is	industrially	applicable”	
should	be	explicitly	disclosed	in	the	description.	It	is	also	abundantly	clear	from	the	case	law	
that	the	assessment	of	industrial	application,	and	indeed	patentability	in	general,	should	be	
done	on	the	basis	of	what	is	disclosed	in	the	patent	application.		
	
																																																						
149	The	Trilateral	Co-operation	is	a	cooperation	between	the	EPO,	the	Japan	Patent	Office	
and	the	United	States	Patent	and	Trademark	Office	(USPTO),	processing	the	majority	of	all	
patent	applications	filed	worldwide	(See	trilateral.net).	
150	Trilateral	project	B3b	–	Trilateral	Project	B3b:	Comparative	study	on	biotechnology	patent	
practices;	Theme:	Nucleic	acid	molecule-related	inventions	whose	functions	are	inferred	
based	on	homology	search	(cases	9	and	10).	Full	text	at	
http://www.trilateral.net/projects/biotechnology/mutual.pdf	(last	accessed	30	May	16).	
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This	follows	explicitly	from	the	decision	in	T	1329/04	(Factor-9/JOHN	HOPKINS),	where	the	
applicant	had	submitted	post-published	evidence	that	proved	that	the	assumptions	made	in	
the	application	regarding	function,	were	in	fact	correct.	The	Board,	however,	states	that	
“[t]his	cannot	be	regarded	as	supportive	of	an	evidence	which	would	have	been	given	in	the	
application	as	filed	since	there	was	not	any.”151	
	
Moreover,	the	Board	goes	on	to	state	that	if	post-published	documentation	was	considered	
when	no	supportive	evidence	was	disclosed	in	the	application,	this	“would	imply	that	the	
recognition	of	a	claimed	subject	matter	as	a	solution	to	a	particular	problem	could	vary	as	
time	went	by.”152	
	
The	industrial	application	should	in	other	words	be	plausible	at	the	filing	date,	by	what	is	
disclosed	in	the	application.		
	
There	are,	however,	several	examples	of	post-published	evidence	being	taken	into	
consideration.	In	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	it	is	listed	as	one	of	
the	technical	circumstances	that	should	be	included	in	the	assessment	of	whether	or	not	a	
“profitable	use”	can	be	derived	from	the	description,153	and	it	is	stated	that	“the	post-
published	evidence	which	confirms	the	preliminary	finding	and	actually	supports	the	
conclusion,	cannot	be	ignored.”154	
	
In	T	1165/06	(IL-17	related	polypeptide/SCHERING),	the	general	assessment	of	Article	57	EPC	
is	rather	brief,	as	the	Board	“is	convinced	that	the	requirements	[…]	are	fulfilled”.155	It	is,	
however,	evident	that	the	Board	uses	post-published	evidence	as	confirmation	that	the	
functions	disclosed	in	the	application	are	plausible.	
	
																																																						
151	T	1329/04	(Factor-9/JOHN	HOPKINS),	point	12	of	the	reasons.	
152	Ibid.	
153	T	898/05	(Hematopoietic	receptor/ZYMOGENETICS),	point	20	of	the	reasons.	
154	Op.cit.,	point	24	of	the	reasons.	
155	T	1165/06	(IL-17	related	polypeptide/SCHERING),	point	25	of	the	reasons	
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Also	in	T	1329/04	it	is	stated	that	post-published	evidence	may	be	taken	into	consideration.	
It	is	however	specified	that	“it	may	not	serve	as	the	sole	basis	to	establish	that	the	
application	solves	indeed	the	problem	it	purports	to	solve.”156	
	
It	seems	clear	then,	that	post-published	evidence	can	be	used	to	support	the	functions	
proposed	in	the	application.	However,	such	evidence	will	only	be	considered	it	if	supports	
evidence	that	is	actually	disclosed	at	the	filing	date.	If	post-published	evidence	was	allowed	
to	be	the	main	proof	of	the	purported	functions,	it	might	lead	to	patent	applications	being	
handed	in	as	soon	as	a	new	gene	or	protein	is	discovered,	in	essence	reserving	that	area	of	
research	and	gambling	on	finding	evidence	to	support	the	supposed	functions	at	a	later	
date.		
	
4 Conclusion	
	
Because	of	the	increasing	importance	of	biotechnology	and	gene	and	protein	based	
therapeutics,	the	number	of	patents	filed	for	inventions	in	the	field	has	been	on	the	rise	for	
the	past	few	decades.	Considering	the	substantial	costs	that	are	associated	with	research	
and	development	of	new	therapeutic	agents,	it	is	imperative	for	those	involved	to	gain	legal	
protection	as	early	as	possible	to	secure	their	investments.		
	
The	presence	of	an	industrial	application	is	effectively	what	separates	a	discovery	from	an	
invention.	Defining	how	the	requirement	for	industrial	applicability	should	be	understood,	is	
therefore	particularly	important	in	order	to	determine	the	earliest	point	a	patent	application	
should	be	filed.		
	
This	paper	has	examined	how	the	requirement	for	industrial	application	is	interpreted	for	
pharmaceutical	and	biotechnological	inventions	by	the	EPO	Board	of	Appeal.	The	
requirement	is	particularly	important	in	this	area,	as	the	potential	practical	use	of	such	
inventions	is	not	always	obvious.		
	
																																																						
156	T	1329/04	(Factor-9/JOHN	HOPKINS),	point	12	of	the	reasons.	
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From	the	evaluation	of	the	Board	of	Appeal’s	interpretation	of	Article	57	EPC,	it	is	first	of	all	
clear	that	the	term	“industry”	should	be	construed	in	a	broad	sense,	including	all	forms	of	
industrial	activity	“that	are	carried	out	continuously,	independently	and	for	financial	
(commercial)	gains”.	
	
This	should	not,	however,	be	taken	to	mean	that	there	is	an	absolute	need	for	potential	
financial	return	to	satisfy	the	requirement	of	industrial	applicability.	Rather,	it	should	be	
understood	to	mean	that	an	invention	must	have	a	beneficial	use,	constituting	a	concrete	
benefit	to	society,	not	just	economic	profit	for	the	applicant.	
	
The	term	“made	or	used	in	industry”	should	therefore	not	be	interpreted	literally	for	
inventions	in	the	biotechnological	and	pharmaceutical	field.	Since	almost	all	such	inventions	
can	technically	be	reproduced	(“made”)	and	used	in	further	research,	a	broad	interpretation	
could	lead	to	a	system	granting	patents	as	hunting	licences.	Inventions	must	therefore	have	
a	clearly	disclosed,	plausible	function	that	can	be	employed	for	e.g.	diagnostic	or	therapeutic	
purposes.	That	the	claimed	substance	can	be	used	as	a	research	tool,	will	rarely	be	sufficient	
to	fulfil	the	requirement	for	industrial	application,	unless	there	is	abundant	evidence	
suggesting	that	the	substance	will	be	of	great	significance	for	the	progression	of	research	in	
the	field.			
	
Results	from	computer-assisted	in	silico	experiments	are	permitted	as	evidence	to	support	
purported	industrial	applications,	and	it	is	not	absolutely	necessary	to	provide	evidence	from	
wet-lab	tests.		The	“probative	value”	of	in	silico	evidence	must,	however,	be	evaluated	on	a	
case-by-case	basis.	This	means	taking	into	account	the	nature	of	the	invention	(such	as	the	
complexity	of	the	biological	processes	the	invention	is	thought	to	affect,	or	the	general	
importance	of	the	discovery	itself)	and	the	prior	art.	There	must	be	a	clear	correlation	
between	gene	sequence,	protein	structure	and	function	on	the	molecular,	cellular	or	
biological	level,	though	it	is	sufficient	that	a	plausible	function	at	one	of	these	levels	is	
disclosed.	If	the	purported	functions	are	based	on	homology	with	other	substances,	a	high	
degree	of	homology	is	required.		
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Evidence	submitted	after	the	filing	date	can	be	taken	into	account,	but	such	evidence	must	
support	what	has	been	disclosed	in	the	application	as	it	is	filed.	A	patent	cannot	be	granted	
solely	based	on	post-published	evidence.		
	
The	examination	presented	in	this	paper	suggests	that	EPO’s	technical	Board	of	Appeal	is	
attempting	to	be	establish	a	stringent	method	for	assessing	the	requirement	of	industrial	
application	for	biotechnological	and	pharmaceutical	inventions,	as	there	is	consistently	little	
deviation	from	existing	case	law.		
	
In	further	research,	a	possible	issue	to	investigate	would	be	if	the	EPO	sets	a	higher	
threshold	for	patenting	biotechnological	and	pharmaceutical	inventions	than	for	inventions	
in	other	fields.	The	fact	that	the	requirement	for	industrial	application	is	not	interpreted	
literally	in	such	cases,	as	it	theoretically	should	be	according	to	Article	31	(1)	of	the	Vienna	
Convention,	certainly	implies	that	a	different	standard	is	expected.	Is	there	perhaps	need	for	
a	separate	requirement	for	inventions	that	are	putative	therapeutic	agents?	This	is	an	
interesting	question,	and	one	that	should	be	answered	as	innovation	in	this	field	is	becoming	
increasingly	important	for	human	health.		
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